1
|
Zhang H, Sun X, Li Z, Liu T, Zhang F, Meng X, Li K, Xu J, He W, Jing B, Wang T, Ni N, Sun B, Yao F, Wu Y, Wang Q, Du J, Chin EY, Zhou BP, Jiang P, Wang L, Deng J. Aldh2 deficiency plays a dual role in lung tumorigenesis and tumor progression. Genes Dis 2024; 11:100999. [PMID: 38292172 PMCID: PMC10825233 DOI: 10.1016/j.gendis.2023.04.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 04/04/2023] [Accepted: 04/10/2023] [Indexed: 02/01/2024] Open
Affiliation(s)
- Hongjia Zhang
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Minister of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Department of Pathology, Kunming Medical University, Kunming, Yunnan 650500, China
| | - Xueqian Sun
- Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China
| | - Zhanming Li
- Center for Traditional Chinese Medicine and Gut Microbiota, Minhang Hospital, Fudan University, Shanghai 201100, China
| | - Tingting Liu
- Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China
| | - Fang Zhang
- Department of Radiation Oncology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, China
| | - Xinyu Meng
- Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China
| | - Kaimi Li
- Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - Jianhua Xu
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Minister of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Department of Pathology, Kunming Medical University, Kunming, Yunnan 650500, China
| | - Wei He
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Minister of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Department of Pathology, Kunming Medical University, Kunming, Yunnan 650500, China
| | - Bo Jing
- Department of Laboratory Medicine, Shanghai Pulmonary Hospital Affiliated Tongji University, Shanghai 200080, China
| | - Tong Wang
- Department of Physiology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261021, China
| | - Na Ni
- Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China
| | - Beibei Sun
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Feng Yao
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Yadi Wu
- Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40506, USA
| | - Qi Wang
- Department of Respiratory Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116023, China
| | - Jing Du
- Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China
| | - Eugene Y. Chin
- Peninsular Cancer Center, Binzhou Medical University, Yantai, Shandong 264003, China
| | - Binhua P. Zhou
- Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40506, USA
| | - Ping Jiang
- Department of Pathology, Kunming Medical University, Kunming, Yunnan 650500, China
| | - Lishun Wang
- Center for Traditional Chinese Medicine and Gut Microbiota, Minhang Hospital, Fudan University, Shanghai 201100, China
| | - Jiong Deng
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Minister of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong 256600, China
- Peninsular Cancer Center, Binzhou Medical University, Yantai, Shandong 264003, China
| |
Collapse
|
2
|
Meng H, Huan Y, Zhang K, Yi X, Meng X, Kang E, Wu S, Deng W, Wang Y. Quiescent Adult Neural Stem Cells: Developmental Origin and Regulatory Mechanisms. Neurosci Bull 2024:10.1007/s12264-024-01206-1. [PMID: 38656419 DOI: 10.1007/s12264-024-01206-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 01/02/2024] [Indexed: 04/26/2024] Open
Abstract
The existence of neural stem cells (NSCs) in the adult mammalian nervous system, although small in number and restricted to the sub-ventricular zone of the lateral ventricles, the dentate gyrus of the hippocampus, and the olfactory epithelium, is a gift of evolution for the adaptive brain function which requires persistent plastic changes of these regions. It is known that most adult NSCs are latent, showing long cell cycles. In the past decade, the concept of quiescent NSCs (qNSCs) has been widely accepted by researchers in the field, and great progress has been made in the biology of qNSCs. Although the spontaneous neuronal regeneration derived from adult NSCs is not significant, understanding how the behaviors of qNSCs are regulated sheds light on stimulating endogenous NSC-based neuronal regeneration. In this review, we mainly focus on the recent progress of the developmental origin and regulatory mechanisms that maintain qNSCs under normal conditions, and that mobilize qNSCs under pathological conditions, hoping to give some insights for future study.
Collapse
Affiliation(s)
- Han Meng
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China
| | - Yu Huan
- Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, 110016, China
| | - Kun Zhang
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China
| | - Xuyang Yi
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China
| | - Xinyu Meng
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China
- School of Life Science and Research Center for Natural Peptide Drugs, Shaanxi Engineering and Technological Research Center for Conversation and Utilization of Regional Biological Resources, Yanan University, Yan'an, 716000, China
| | - Enming Kang
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China
| | - Shengxi Wu
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.
| | - Wenbing Deng
- School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, 510631, China.
| | - Yazhou Wang
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.
| |
Collapse
|
3
|
Zhou S, Meng X, Chen Y, Li J, Lin S, Han C, Ji X, Chang Z, Pan A. Zinc-ion Anchor Induced Highly Reversible Zn Anodes for High Performance Zn-ion Batteries. Angew Chem Int Ed Engl 2024:e202403050. [PMID: 38579168 DOI: 10.1002/anie.202403050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 03/25/2024] [Accepted: 04/02/2024] [Indexed: 04/07/2024]
Abstract
Unstable Zn interface with serious detrimental parasitic side-reactions and uncontrollable Zn dendrites severely plagues the practical application of aqueous zinc-ion batteries. The interface stability was closely related to the electrolyte configuration and Zn2+ depositional behavior. In this work, a unique Zn-ion anchoring strategy is originally proposed to manipulate the coordination structure of solvated Zn-ions and guide the Zn-ion depositional behavior. Specifically, the amphoteric charged ion additives (denoted as DM), which act as zinc-ion anchors, can tightly absorb on the Zn surface to guide the uniform zinc-ion distribution by using its positively charged -NR4+ groups. While the negatively charged -SO3- groups of DM on the other hand, reduces the active water molecules within solvation sheaths of Zn-ions. Benefiting from the special synergistic effect, Zn metal exhibits highly ordered and compact (002) Zn deposition and negligible side-reactions. As a result, the advanced Zn||Zn symmetric cell delivers extraordinarily 7000 hours long lifespan (0.25 mAh cm-2, 0.25 mAh cm-2). Additionally, based on this strategy, the NH4V4O10llZn pouch-cell with low negative/positive capacity ratio (N/P ratio=2.98) maintains 80.4% capacity retention for 180 cycles. A more practical 4 cm*4 cm sized pouch-cell could be steadily cycled in a high output capacity of 37.0 mAh over 50 cycles.
Collapse
Affiliation(s)
- Shuang Zhou
- Central South University, School of Materials Science & Engineering, Central South University,, 932#, Lushan South Road, Yuelu District, 410083, Changsha, CHINA
| | - Xinyu Meng
- Central South University, School of Materials Science & Engineering, , CHINA
| | - Yining Chen
- Central South University, School of Materials Science & Engineering, 932#, Lushan South Road, Changsha, CHINA
| | - Jianwen Li
- Central South University, School of Materials Science & Engineering, 932#, Lushan South Road, Central South University, CHINA
| | - Shangyong Lin
- Central South University, School of Mineral Processing and Bioengineering, 932#, Lushan South Road, Central South University, Changsha, CHINA
| | - Chao Han
- Central South University, School of Materials Science & Engineering, 932#, Lushan South Road, Central South University, CHINA
| | - Xiaobo Ji
- Central South University, College of Chemistry and Chemical Engineering, Changsha, CHINA
| | - Zhi Chang
- Central South University, School of Materials Science & Engineering, Changsha, CHINA
| | - Anqiang Pan
- Central South University, School of Materials Science & Engineering, 932#, Lushan South Road, Central South University, 410083, Changsha, CHINA
| |
Collapse
|
4
|
Chen Y, Liu Q, Meng X, Zhao L, Zheng X, Feng W. Catalpol ameliorates fructose-induced renal inflammation by inhibiting TLR4/MyD88 signaling and uric acid reabsorption. Eur J Pharmacol 2024; 967:176356. [PMID: 38325797 DOI: 10.1016/j.ejphar.2024.176356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 12/15/2023] [Accepted: 01/23/2024] [Indexed: 02/09/2024]
Abstract
Accumulating evidence suggests that excess fructose uptake induces metabolic syndrome and kidney injury. Here, we primarily investigated the influence of catalpol on fructose-induced renal inflammation in mice and explored its potential mechanism. Treatment with catalpol improved insulin sensitivity and hyperuricemia in fructose-fed mice. Hyperuricemia induced by high-fructose diet was associated with increases in the expressions of urate reabsorptive transporter URAT1 and GLUT9. Treatment with catalpol decreased the expressions of URAT1 and GLUT9. Futhermore, treatment with catalpol ameliorated renal inflammatory cell infiltration and podocyte injury, and these beneficial effects were associated with inhibiting the production of inflammatory cytokines including IL-1β, IL-18, IL-6 and TNF-α. Moreover, fructose-induced uric acid triggers an inflammatory response by activiting NLRP3 inflammasome, which then processes pro-inflammatory cytokines. Treatment with catalpol could inhibit the activation of NLRP3 inflammasome as well. Additionally, TLR4/MyD88 signaling was activated in fructose-fed mice, while treatment with catalpol inhibited this activation along with promoting NF-κB nuclear translocation in fructose-fed mice. Thus, our study demonstrated that catalpol could ameliorate renal inflammation in fructose-fed mice, attributing its beneficial effects to promoting uric acid excretion and inhibit the activation of TLR4/MyD88 signaling.
Collapse
Affiliation(s)
- Yan Chen
- College of Pharmacy, Henan University of Chinese Medicine, China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, China
| | - Qingpu Liu
- College of Pharmacy, Henan University of Chinese Medicine, China; The Engineering and Technology Research Center of Quality Control and Evaluation for Chinese Medicine Development of Henan Province, China
| | - Xinyu Meng
- College of Pharmacy, Henan University of Chinese Medicine, China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, China
| | - Liqin Zhao
- College of Pharmacy, Henan University of Chinese Medicine, China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, China
| | - Xiaoke Zheng
- College of Pharmacy, Henan University of Chinese Medicine, China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, China.
| | - Weisheng Feng
- College of Pharmacy, Henan University of Chinese Medicine, China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, China.
| |
Collapse
|
5
|
Zhou Y, Xue W, Meng X, Bhandari A, Zeng H, KC R, Hirachan S, Xia E. GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer. Breast Cancer (Dove Med Press) 2024; 16:71-89. [PMID: 38476642 PMCID: PMC10929243 DOI: 10.2147/bctt.s451054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 02/14/2024] [Indexed: 03/14/2024]
Abstract
Background Breast cancer (BC) is increasingly becoming the primary reason for death in women, which sounded the alarm. Thus, finding a novel management target for BC is imminent. Materials and Methods The data on gene expression and clinicopathological characteristics were downloaded from The Cancer Genome Atlas (TCGA). The expression of GNPNAT1 in 40 paired breast cancer and adjacent tissues was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Univariate and Multivariate logistic regression methodology was applied to analyze the prognostic factors for lymph node metastasis (LNM). Based on the status of breast cancer-relative receptors, patients were distributed into six groups, and then the Kaplan-Meier survival analysis with a Log rank test was applied to investigate the involvement among the expression of GNPNAT1 and overall survival (OS). Results We found higher expression of GNPNAT1 was connected with poor survival in breast cancer by COX regulation analysis. GO, KEGG, and GSEA analysis prompted that GNPNAT1 was connected with the defense mechanism of cells, cell proliferation, and division. Immunization infiltration analysis showed that high GNPNAT1 was negatively connected with 16 immunization infiltration cell types and positively connected with four immunization infiltration cell types. Conclusion As a whole, our results indicated that GNPNAT1 might be a probable biomarker for diagnosis and prognosis in breast cancer.
Collapse
Affiliation(s)
- Yuying Zhou
- Department of Oncology and Hematology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, People’s Republic of China
| | - Wu Xue
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
| | - Xinyu Meng
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
| | - Adheesh Bhandari
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
- Department of Surgery, Breast and Thyroid Unit, Primera Hospital, Kathmandu, Nepal
| | - Hanqian Zeng
- Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, People’s Republic of China
| | - Rajan KC
- Central Department of Zoology, Tribhuvan University, Kirtipur, Kathmandu, Nepal
| | - Suzita Hirachan
- Department of General Surgery, Breast and Thyroid Unit, Tribhuvan University, Teaching Hospital, Kathmandu, Nepal
| | - Erjie Xia
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
| |
Collapse
|
6
|
Wen Y, Zhang S, Meng X, Zhao C, Hou B, Zhu X, Cai W, Zhou Y, Qiu L, Sun H. Water extracts of Tibetan medicine Wuweiganlu attenuates experimental arthritis via inducing macrophage polarization towards the M2 type. J Ethnopharmacol 2024; 318:116934. [PMID: 37480967 DOI: 10.1016/j.jep.2023.116934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Revised: 07/15/2023] [Accepted: 07/17/2023] [Indexed: 07/24/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Wuweiganlu (WGL) is a well-known formulation described in the "Four Medical Scriptures of Tibetan medicine", which is mainly used for the treatment of Rheumatoid Arthritis (RA) and other chronic ailments prescribed by Tibetan medicine. Nonetheless, the active constituents present in the water extracts of Wuweiganlu (WGLWE) specifically targeting arthritis treatment are largely unknown. AIM OF THE STUDY The aim of this study is to explore the effects and underlying mechanisms of the active components in WGLWE on RA. MATERIALS AND METHODS We utilized ultra-performance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC-Q-TOF-MS) to identify the main chemical compositions of WGLWE. The polarization effect of WGLWE on bone marrow-derived macrophages (BMDM) was determined. A rat model of collagen-induced arthritis (CIA) was established by injecting an emulsion of bovine type II collagen mixed with an equal volume of incomplete Freund's adjuvant into the tail, paw and back of rats. A WGLWE-based ointment was topically applied to the legs and paws of the rats for 30 days. The rats' ankles were photographed to measure the degree of swelling. Micro-CT was used to image the knee joint and paw of rats, and the bone mineral density (BMD) and bone volume fraction (BV/TV) of knee joint in rats were analyzed. High-frequency ultrasound imaging of the rat knee joint was performed to observe knee joint effusion. Further, the serum levels of tumor necrosis factor (TNF-α), interleukin-6 (IL-6), IL-10, and arginine (Arg-1) in CIA rats were detected by enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry (IHC) and immunofluorescence (IF) co-staining were employed to detect the expression levels of inflammatory factors in synovium. RESULTS A total of 28 main components were identified in WGLWE, and these compounds can directly bind to the inflammatory pathway proteins such as JAK2, NFκB and STAT3. In vitro experiments demonstrated that WGLWE promoted the transformation of M1 macrophages into M2 macrophages and suppressed the release of proinflammatory cytokines TNF-α and IL-6. In vivo studies showed that WGLWE effectively reduced ankle swelling, alleviated knee joint effusion, and improved BV/TV while also reducing synovial inflammation levels. Furthermore, WGLWE compounds induced the transition of M1-type macrophages to M2-type macrophages in synovial tissue, resulting in decreased secretion of inflammatory factors TNF-α, WGLWE improved the synovial inflammatory state. CONCLUSION Our results indicated that WGLWE alleviated joint inflammation in CIA rats and the underlying mechanism may be related to inducing the transformation of bone marrow-derived M1 macrophages to M2 macrophages, leading to an increase in the secretion of anti-inflammatory factors and a decrease in pro-inflammatory factors. Therefore, WGLWE may be used as a potential herbal preparation for the treatment of RA.
Collapse
Affiliation(s)
- Yuanyuan Wen
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Shijie Zhang
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Xinyu Meng
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Chenyang Zhao
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Bao Hou
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Xuexue Zhu
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Weiwei Cai
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Yuetao Zhou
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China
| | - Liying Qiu
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China.
| | - Haijian Sun
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing, 210009, China; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117600, Singapore.
| |
Collapse
|
7
|
Cao S, Li Y, Song R, Meng X, Fuchs M, Liang C, Kachler K, Meng X, Wen J, Schlötzer-Schrehardt U, Taudte V, Gessner A, Kunz M, Schleicher U, Zaiss MM, Kastbom A, Chen X, Schett G, Bozec A. L-arginine metabolism inhibits arthritis and inflammatory bone loss. Ann Rheum Dis 2024; 83:72-87. [PMID: 37775153 PMCID: PMC10803985 DOI: 10.1136/ard-2022-223626] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 08/29/2023] [Indexed: 10/01/2023]
Abstract
OBJECTIVES To investigate the effect of the L-arginine metabolism on arthritis and inflammation-mediated bone loss. METHODS L-arginine was applied to three arthritis models (collagen-induced arthritis, serum-induced arthritis and human TNF transgenic mice). Inflammation was assessed clinically and histologically, while bone changes were quantified by μCT and histomorphometry. In vitro, effects of L-arginine on osteoclast differentiation were analysed by RNA-seq and mass spectrometry (MS). Seahorse, Single Cell ENergetIc metabolism by profilIng Translation inHibition and transmission electron microscopy were used for detecting metabolic changes in osteoclasts. Moreover, arginine-associated metabolites were measured in the serum of rheumatoid arthritis (RA) and pre-RA patients. RESULTS L-arginine inhibited arthritis and bone loss in all three models and directly blocked TNFα-induced murine and human osteoclastogenesis. RNA-seq and MS analyses indicated that L-arginine switched glycolysis to oxidative phosphorylation in inflammatory osteoclasts leading to increased ATP production, purine metabolism and elevated inosine and hypoxanthine levels. Adenosine deaminase inhibitors blocking inosine and hypoxanthine production abolished the inhibition of L-arginine on osteoclastogenesis in vitro and in vivo. Altered arginine levels were also found in RA and pre-RA patients. CONCLUSION Our study demonstrated that L-arginine ameliorates arthritis and bone erosion through metabolic reprogramming and perturbation of purine metabolism in osteoclasts.
Collapse
Affiliation(s)
- Shan Cao
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
- Department of Rheumatology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yixuan Li
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
- Department of Rheumatology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Rui Song
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
- Department of Rheumatology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xianyi Meng
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
| | - Maximilian Fuchs
- Chair of Medical Informatics, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany
- Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
| | - Chunguang Liang
- Chair of Medical Informatics, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany
- Bioinformatics, Biocenter, University of Würzburg Am Hubland, Würzburg, Germany
| | - Katerina Kachler
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
| | - Xinyu Meng
- Department of Rheumatology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jinming Wen
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
- Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Ursula Schlötzer-Schrehardt
- Department of Ophthalmology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
| | - Verena Taudte
- Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany
- Core Facility for Metabolomics, Department of Medicine, Philipps University of Marburg, Marburg, Germany
| | - Arne Gessner
- Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany
| | - Meik Kunz
- Chair of Medical Informatics, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany
- Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
| | - Ulrike Schleicher
- Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
| | - Mario M Zaiss
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
| | - Alf Kastbom
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
| | - Xiaoxiang Chen
- Department of Rheumatology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Georg Schett
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
| | - Aline Bozec
- Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Shanghai, Germany
| |
Collapse
|
8
|
Zhang L, Du F, Jin Q, Sun L, Wang B, Tan Z, Meng X, Huang B, Zhan Y, Su W, Song R, Wu C, Chen L, Chen X, Ding X. Identification and Characterization of CD8 + CD27 + CXCR3 - T Cell Dysregulation and Progression-Associated Biomarkers in Systemic Lupus Erythematosus. Adv Sci (Weinh) 2023; 10:e2300123. [PMID: 37875396 PMCID: PMC10724430 DOI: 10.1002/advs.202300123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 08/04/2023] [Indexed: 10/26/2023]
Abstract
Systemic Lupus Erythematosus (SLE) etiopathogenesis highlights the contributions of overproduction of CD4+ T cells and loss of immune tolerance. However, the involvement of CD8+ T cells in SLE pathology and disease progression remains unclear. Here, the comprehensive immune cell dysregulation in total 263 clinical peripheral blood samples composed of active SLE (aSLE), remission SLE (rSLE) and healthy controls (HCs) is investigated via mass cytometry, flow cytometry and single-cell RNA sequencing. This is observed that CD8+ CD27+ CXCR3- T cells are increased in rSLE compare to aSLE. Meanwhile, the effector function of CD8+ CD27+ CXCR3- T cells are overactive in aSLE compare to HCs and rSLE, and are positively associated with clinical SLE activity. In addition, the response of peripheral blood mononuclear cells (PBMCs) is monitored to interleukin-2 stimulation in aSLE and rSLE to construct dynamic network biomarker (DNB) model. It is demonstrated that DNB score-related parameters can faithfully predict the remission of aSLE and the flares of rSLE. The abundance and functional dysregulation of CD8+ CD27+ CXCR3- T cells can be potential biomarkers for SLE prognosis and concomitant diagnosis. The DNB score with accurate prediction to SLE disease progression can provide clinical treatment suggestions especially for drug dosage determination.
Collapse
Affiliation(s)
- Lulu Zhang
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
- State Key Laboratory of Oncogenes and Related GenesInstitute for Personalized MedicineSchool of Biomedical EngineeringShanghai Jiao Tong UniversityShanghai200001China
| | - Fang Du
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
- State Key Laboratory of Oncogenes and Related GenesInstitute for Personalized MedicineSchool of Biomedical EngineeringShanghai Jiao Tong UniversityShanghai200001China
| | - Qiqi Jin
- Key Laboratory of Systems BiologyCenter for Excellence in Molecular Cell ScienceShanghai Institute of Biochemistry and Cell BiologyChinese Academy of SciencesShanghai200031China
- University of Chinese Academy of SciencesBeijing100049China
- School of Life Science and TechnologyShanghaiTech UniversityShanghai201210China
| | - Li Sun
- Department of Rheumatology and ImmunologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhou325000China
| | - Boqian Wang
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
- State Key Laboratory of Oncogenes and Related GenesInstitute for Personalized MedicineSchool of Biomedical EngineeringShanghai Jiao Tong UniversityShanghai200001China
| | - Ziyang Tan
- Science for Life LaboratoryDepartment of Women's and Children's HealthKarolinska InstitutetSolna17121Sweden
| | - Xinyu Meng
- State Key Laboratory of Oncogenes and Related GenesInstitute for Personalized MedicineSchool of Biomedical EngineeringShanghai Jiao Tong UniversityShanghai200001China
| | - Baozhen Huang
- Department of Chemical PathologyLi Ka Shing Institute of Health SciencesFaculty of MedicineThe Chinese University of Hong KongHong Kong999077China
| | - Yifan Zhan
- Drug DiscoveryShanghai Huaota Biopharmaceutical Co. Ltd.Shanghai200131China
| | - Wenqiong Su
- State Key Laboratory of Oncogenes and Related GenesInstitute for Personalized MedicineSchool of Biomedical EngineeringShanghai Jiao Tong UniversityShanghai200001China
| | - Rui Song
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
- Nantong First People's HospitalAffiliated Hospital 2 of Nantong UniversityNantong Hospital of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
| | - Chunmei Wu
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
| | - Luonan Chen
- Key Laboratory of Systems BiologyCenter for Excellence in Molecular Cell ScienceShanghai Institute of Biochemistry and Cell BiologyChinese Academy of SciencesShanghai200031China
- School of Life Science and TechnologyShanghaiTech UniversityShanghai201210China
- Key Laboratory of Systems Health Science of Zhejiang ProvinceSchool of Life ScienceHangzhou Institute for Advanced StudyUniversity of Chinese Academy of SciencesChinese Academy of SciencesHangzhou310024China
| | - Xiaoxiang Chen
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
| | - Xianting Ding
- Department of RheumatologyShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical EngineeringShanghai200030China
- State Key Laboratory of Oncogenes and Related GenesInstitute for Personalized MedicineSchool of Biomedical EngineeringShanghai Jiao Tong UniversityShanghai200001China
| |
Collapse
|
9
|
Cai G, Yu J, Meng X. TFAM Modulates Cardiomyocytes Pyroptosis Induced by Ionizing Radiation through mtDNA/TLR9/NF-kB Pathway. Int J Radiat Oncol Biol Phys 2023; 117:S119-S120. [PMID: 37784308 DOI: 10.1016/j.ijrobp.2023.06.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Mitochondrial transcription factor A (TFAM) is a pivotal factor for regulating mitochondrial DNA (mtDNA) replication, transcription and biogenesis. Previous studies have reported that cytosolic mtDNA stress can lead to cardiomyocytes pyroptosis, which is characterized by inflammasome formation. In this study, we attempted to investigate the mechanism of TFAM regulate cardiomyocytes pyroptosis induced by ionizing radiation. MATERIALS/METHODS The peripheral blood serum of patients with esophageal cancer before and after definitive chemoradiotherapy was collected for Luminex multiplex cytokine assays. C57BL/6 mice were irradiated with the whole heart using small animal radiation research platform (SARRP) to construct a radiation-induced myocardial damage (RIMD) mouse model, and the ventricular function was evaluated using 9.4T Bruker magnetic resonance (MR) scanner. The function changes of cardiomyocytes exposed to radiation were observed in vitro and in vivo after knocking out GSDMD. Furthermore, the changes of mitochondrial function, the levels of cytosolic mtDNA, and the protein levels of NF-kB and pyroptosis pathway in irradiated cardiomyocytes were analyzed by knockdown and overexpression of TFAM in vitro and in vivo. RESULTS By multifactor cytokine assays we found that pyroptosis related IL-1β and IL-18 were significantly increased in patients with high mean heart dose (MHD) after radiotherapy, while those with low MHD were not significantly increased after radiotherapy. Next, we successfully constructed the RIMD mouse model using a single heart irradiation of 20 Gy. We found that the gene expression of pyroptosis pathway was significantly up-regulated after cardiac irradiation by myocardial tissue transcriptomic sequencing. Compared with wild-type (WT) mice, cardiac systolic function of Gsdmd-/- mice was significantly improved at 1, 2, 6, 12, and 24 weeks after heart irradiation. In vitro, we also demonstrated increased viability of irradiated cardiomyocytes by knocking out GSDMD. In vitro and in vivo experiments confirmed the expression of TFAM decreased after radiation. By overexpression of TFAM, we found that irradiated cardiomyocytes showed improved mitochondrial function, decreased release of mtDNA into cytoplasm through mitochondrial permeability transition pores (mPTPs), decreased binding of cytosolic mtDNA to TLR9, and decreased expression of NF-kB and pyroptosis pathway proteins. Dual luciferase gene reporter assays and Chromatin immunoprecipitation (CHIP) assay confirmed that p65 could bind the NLRP3 promoter region. In addition, we found that ventricular function deteriorated and improved in mice with knockdown and overexpression of TFAM through adeno-associated virus serotype 9 (AAV9), respectively. CONCLUSION Our study indicated that TFAM regulate irradiated cardiomyocytes pyroptosis through mtDNA/TLR9/NF-kB pathway. We provide a novel mechanism of RIMD, revealing an underappreciated intervention target for RIMD.
Collapse
Affiliation(s)
- G Cai
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - J Yu
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - X Meng
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
10
|
Wang L, Zou B, Huang W, Shao Q, Meng X, Tang X, Zhang P, Hu X, Zhang Y, Guo J, Fu L, Zhao W, Zhao C, Yuan J, Yu J, Chen D. Safety and Efficacy Analysis of Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated with SHR-1316 Plus Chemotherapy and Sequential Chest Radiotherapy as First-Line Therapy from a Phase II Trial. Int J Radiat Oncol Biol Phys 2023; 117:S58-S59. [PMID: 37784531 DOI: 10.1016/j.ijrobp.2023.06.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) CAPSTONE-1, a phase 3 trial, showed that SHR-1316 (PD-L1 antibody) combined with standard first-line chemotherapy could prolong overall survival (OS) in patients (pts) with ES-SCLC. The CREST trial reported consolidative thoracic radiotherapy (TRT) of 30 Gy in 10 fractions provided a 10% 2-year OS benefit and more intensive TRT should be investigated in ES-SCLC. In the era of immunotherapy, the role of TRT also needs further exploration. Therefore, we designed this clinical trial to investigate the efficacy and safety of SHR-1316 plus first-line chemotherapy followed by TRT combined with SHR-1316. MATERIALS/METHODS Key inclusion criteria were pts aged 18-75 years, with previously untreated histologically or cytologically confirmed ES-SCLC, and an ECOG performance status of 0-1. Eligible pts would receive 4∼6 cycles of SHR-1316 (20mg/kg, D1, q3w) combined with EP/EC (etoposide, 100mg/m2, D1-5, q3w and cisplatin, 75mg/m², D1-3, q3w or carboplatin, AUC = 5, D1, q3w), followed by SHR-1316 combined with TRT (≥3 Gy*10 f or ≥2 Gy*25 f, involved-field irradiation), and then the maintenance therapy with SHR-1316 until disease progression or intolerable adverse events (AEs). The main endpoints included ORR, PFS and safety. RESULTS From October 2020 to January 2023, 33 pts received SHR-1316 and sequential consolidative TRT. Among them, 19 pts received high-dose TRT (>3 Gy*10 f or ≥2 Gy*25 f) and 14 pts received low-dose TRT (≤3 Gy*10 f or<2 Gy*25 f). The median age was 62 (range: 38-73). Most pts were male (28, 84.8%), former smokers (22, 66.7%) with an ECOG performance status 1 (32, 97%). Ten (30.3%) pts were diagnosed with brain metastasis and 10 (30.3%) pts had liver metastasis at baseline. At the data cutoff date, 9 pts remained on treatment, the average number of treatment cycles was 9.2. 33 pts had at least one 1 post-treatment tumor assessment. The confirmed ORR and DCR were 90.9% (30/33) and 100% (33/33) in all pts, were 89.5% (17/19) and 100% (19/19) in high-dose TRT group, and were 92.9% (13/14) and 100% (14/14) in low-dose TRT group. The median PFS was 10.2(CI: 5.8∼14.7) months in all pts, was 7 (CI: 3.8∼10.2) months in high-dose TRT group and 10.4 (CI: 8.4∼12.3) months in low-dose TRT group. AEs occurred in 27 (81.8%) pts and grade 3 or 4 AEs occurred in 20 (60.6%) pts. The most common grade 3 or 4 AEs included neutropenia (15, 45.5%), leukopenia (8, 24.2%), lymphocytopenia (5, 15.2%), pneumonia (3, 9.1%), anemia (3, 9.1%) and thrombocytopenia (2, 6.1%). CONCLUSION SHR-1316 plus chemotherapy and sequential TRT as first-line therapy for ES-SCLC showed promising efficacy and acceptable safety. There is no significant difference between high-dose and low-dose TRT groups in terms of safety and efficacy according to current data.
Collapse
Affiliation(s)
- L Wang
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - B Zou
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - W Huang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Q Shao
- Shandong Cancer Hospital and Institute, Jinan, China
| | - X Meng
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - X Tang
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, China
| | - P Zhang
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - X Hu
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - Y Zhang
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, China
| | - J Guo
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, China
| | - L Fu
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - W Zhao
- Shandong Cancer Hospital, Shandong University, Jinan, China
| | - C Zhao
- Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
| | - J Yuan
- Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
| | - J Yu
- Shandong Cancer Hospital, Shandong University, Jinan, Shandong, China
| | - D Chen
- Shandong Cancer Hospital, Shandong University, Jinan, China
| |
Collapse
|
11
|
Wang Z, Yang B, Meng X, Liang Y, Pang T, Qiu J. Performance Evaluation in Automatic Plan Generation for Ethos Intelligent Optimization Engine. Int J Radiat Oncol Biol Phys 2023; 117:e736. [PMID: 37786140 DOI: 10.1016/j.ijrobp.2023.06.2263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To evaluate the automatic optimization performance and clinical feasibility of the Intelligent Optimization Engine (IOE) of Ethos online adaptive radiotherapy platform. MATERIALS/METHODS Eleven patients with cervical cancer treated with Halcyon accelerator were retrospectively selected. All the patients manually planned with four full arc volume rotating intensity modulated radiotherapy (VMAT) (Manual-4Arc), and the prescription dose was 45 Gy/25F. All patient images and structures were imported into Ethos simulator, and clinical goals were added appropriately based on clinical requirements. The target coverage was normalized to 95%. 7F, 9F, 12F IMRT plans and 2Arc, 3Arc VMAT plans were automatically generated by IOE. Dosimetric index comparisons were made among the Manual-4Arc plans and five group IOE generated plan to evaluate the automatic optimization performance of IOE. RESULTS In terms of hot dose area, for PTV, D1% of IMRT-12F plans was the lowest, and there were significant differences between IMRT-12F plans and Manual-4Arc plans (46.936 ± 0.241 vs 48.639 ± 2.395, p = 0.004); In terms of target coverage, the CTVs of all groups meet clinical requirements. Although the Ethos online adaptive plans have been normalized during planning, the PTV coverage is slightly insufficient (12F: 94.913 ± 0.154; 9F: 94.585 ± 1.148). For OARs close to target, such as bladder, V30Gy, V40Gy and Dmean have significant differences among the six group plans. The order of bladder dose is basically followed by IMRT-12F CONCLUSION The plans automatically generated by Ethos IOE can achieve similar performance as the manual plan, and the automatically generated IMRT-12F and 9F plans are preferred for clinical use.
Collapse
Affiliation(s)
- Z Wang
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - B Yang
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - X Meng
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Y Liang
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - T Pang
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - J Qiu
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| |
Collapse
|
12
|
Kun Z, Shen J, Meng X, Yang B, Ma J, Hou X, Hu K, Zhang F. Dose DIBH Really Reduce the Subclinical Cardiac Acute Injury? Analysis of Clinical Real World from Our Institute. Int J Radiat Oncol Biol Phys 2023; 117:e189. [PMID: 37784820 DOI: 10.1016/j.ijrobp.2023.06.1050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The study is aim to investigate whether Deep-inspirational breath-hold (DIBH), compared with free breathing (FB), could provide a short-term cardiac benefit in patients with early left breast cancer after breast-conserving surgery combined whole breast radiotherapy. MATERIALS/METHODS A total of 78 patients with early stage left breast cancer treated with radiotherapy between 2021-2022 after breast-conserving surgery were enrolled. Among them, 32 cases were treated with DIBH technique and 46 cases were treated with free breathing. Patients with previous cardiac disease such as coronary artery disease were excluded. We performed myocardial enzymes, ECG, and ECHO in all patients within 2 weeks before, during, and 6 months after radiotherapy. The results of the two groups were compared using nonparametric tests and chi-square tests, and P < 0.05 indicated statistical significance. Where subclinical acute cardiac injury was defined as new above-normal myocardial enzymes and/or electrocardiographic ST-T or T-wave changes and/or ECHO abnormalities after the start of radiotherapy. RESULTS The median follow-up of patients was 6 months and the mean age of patients was 52.3 years for FB and 44.9 years for DIBH. There were no significant differences in staging, molecular subtype, chemotherapy and endocrine therapy history. The proportion of subclinical acute cardiac injury was smaller in the DIBH group compared to the FB group (DIBH = 31/46 and FB = 28/32, p = 0.042). The most sensitive of the subclinical acute cardiac injury events were detected by myocardial enzymes rising, with cTnI (p = 0.034) and NT-proBNP (p = 0.023) appearing significantly lower in the DIBH patients during radiotherapy. The difference of cTnI between 2 groups at 6 months after radiotherapy became non-significant. In contrast, CK-MB was higher in DIBH compared with FB only 6 months after radiotherapy (p = 0.006). The differences in ECG and ECHO were not significant between the two groups. CONCLUSION After breast-conserving surgery combined with radiotherapy for left early breast cancer, DIBH compared to FB reduces the proportion of acute subclinical cardiac injury that occurs with the most sensitive changes in myocardial enzymes. Subsequent studies will explore the relationship between the short-term subclinical injury and irradiated dose, as well as long term cardiac injury.
Collapse
Affiliation(s)
- Z Kun
- Department of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - J Shen
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - X Meng
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - B Yang
- Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - J Ma
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - X Hou
- Department of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - K Hu
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - F Zhang
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
13
|
Cai G, Meng X, Yu J. The Predictive Value of Changes in Basal Myocardial F-18 Fluorodeoxyglucose Uptake for Cardiotoxicity in Locally Advanced Esophageal Cancer Patients Receiving Definitive Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e285. [PMID: 37785059 DOI: 10.1016/j.ijrobp.2023.06.1272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To investigate the predictive value of changes in myocardial 18F-FDG uptake for major adverse cardiac events (MACEs) in locally advanced esophageal cancer patients receiving definitive radiotherapy. MATERIALS/METHODS Between August 2012 and January 2018, 400 patients with stage II-III esophageal cancer receiving definitive radiotherapy at two institutions were divided into the training (n = 240) and external validation cohorts (n = 160). All patients underwent FDG-PET imaging within 1 week before treatment and 3 months after treatment. Myocardium delineation was performed by Carimas software (version 2.10) based on the AHA 17-segment model. When contouring the left ventricle, the myocardium was automatically divided into basal (segments 1-6), middle (segments 7-12), and apical (segments 13-16) regions, and the mean dose and FDG uptake parameters of each region were obtained by Carimas. Our primary endpoint was MACEs. Patient clinicopathologic factors, dosimetric parameters for the whole heart and cardiac substructures, and myocardial changes within the three regions on 18F-FDG PET were utilized to seek the best predictive models for cardiotoxicity. To avoid multicollinearity between dose-volume histogram (DVH) parameters, we selected the variables with the lowest Akaike Information Criterion (AIC) value from the DVH parameters of the same cardiac structure for the actual modeling procedure. Competing risk analysis and Cox regressions analysis were performed. The predictive performance of the models was evaluated using the area under the receiver operating characteristic curve (AUC) and Brier score. RESULTS At a median follow-up interval of 78 months, 28 patients (11.7%) developed MACEs. The basal region of the myocardium received the highest radiation dose, followed by the middle and the apex region. The basal myocardial SUVmax and SUVmean significantly increased after radiotherapy while the apical and middle myocardial SUVmax and SUVmean not significantly increased. In univariate analysis, age, pre-existing cardiac disease, changes in pre- and post-treatment basal myocardial SUVmax and SUVmean (∆SUVmax and ∆SUVmean), and dosimetric parameters for MHD, mean LCX, mean LAD, and mean LV dose were associated with an increased hazard of MACEs. Multivariate analysis showed that basal ∆SUVmean retained significance after adjusting for age, pre-existing cardiac disease, and dosimetric parameters for whole heart and cardiac substructures. The AUCs and Brier scores demonstrated favorable predictive accuracies of the model's integrating variables with significant difference in multivariate analysis when predicting MACEs in the training and validation cohorts. CONCLUSION ∆SUVmean was an independent indicator of MACE in locally advanced esophageal cancer patients receiving definitive radiotherapy. Changes in basal myocardial FDG uptake is a promising biomaker for predicting radiation-induced cardiotoxicity.
Collapse
Affiliation(s)
- G Cai
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - X Meng
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - J Yu
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
14
|
Peng J, Zhang L, Wang L, Feng H, Yao D, Meng R, Liu X, Li X, Liu N, Tan B, Huang Z, Li S, Meng X. PD-L1 Inhibitors Combined with Thoracic Radiotherapy in First-Line Treatment of Extensive Stage Small Cell Lung Cancer: A Propensity Score-Matched, Real-World Study. Int J Radiat Oncol Biol Phys 2023; 117:S127-S128. [PMID: 37784327 DOI: 10.1016/j.ijrobp.2023.06.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival of extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy is controversial. This study aims to explore the efficacy and safety of adding TRT to the combination of PD-L1 inhibitors and chemotherapy. MATERIALS/METHODS Thepatients who received PD-L1 inhibitors combined with platinum-based chemotherapy as the first-line treatment of ES-SCLC from January 2019 to December 2021 were retrospectively collected. According to whether they received TRT, they were divided into two groups, and the follow-up analysis was performed. Propensity score matching (PSM) in with a 1:1 ratio was performed to balance the baseline characteristics of the two cohorts. The endpoints were progression-free survival (PFS) and OS. RESULTS A total of 211 patients with ES-SCLC were enrolled, of whom 70 (33.2%) patients received standard therapy plus TRT as first-line treatment, and 141 (66.8%) patients in the control group received PD-L1 inhibitors plus chemotherapy. After PSM, a total of 65 pairs of patients were enrolled in the analysis. There were no significant differences in baseline characteristics between the two groups of patients who received TRT and those who did not. In all patients, the median PFS (mPFS) in the TRT group and the non-TRT groupwere 9.5 months and 7.2 months, respectively, with HR = 0.60 (95% CI 0.41-0.87, p = 0.007). The median OS (mOS) in the TRT group was also significantly longer than that in the non-TRT group (24.1 months vs. 18.5 months, HR = 0.53, 95% CI 0.32-0.85, p = 0.009). Multivariable analysis showed that baseline liver metastasis and bone metastasis were independent prognostic factors for OS. In terms of safety, immunotherapy combined with thoracic radiotherapy increased the incidence of treatment-related pneumonia (p<0.001), most of which were grade 1-2. CONCLUSION This real-world study shows that adding TRT to durvalumab or atezolizumab plus chemotherapy significantly improves survival in ES-SCLC. It leads to more treatment-related pneumonia, but most of them can be relieved after symptomatic treatment. This treatment model deserves to be explored in prospective clinical trials.
Collapse
Affiliation(s)
- J Peng
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L Zhang
- Department of Thoracic Department, Hunan Cancer Hospital, Changsha, China
| | - L Wang
- Department of Medical Oncology, Baotou Cancer Hospital, Baotou, China
| | - H Feng
- Department of Clinical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - D Yao
- Department of Medical Oncology, Chaoyang Second Hospital, Chaoyang, China
| | - R Meng
- Department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - X Liu
- Department of Oncology Department, Jinzhou Medical University, Jinzhou, China, Jinzhou, China
| | - X Li
- Department of Respiratory and Critical Care, Chifeng Municipal Hospital, Chifeng, China
| | - N Liu
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China
| | - B Tan
- QILU HOSPITAL OF SHANDONG UNIVERSITY, Jinan, China
| | - Z Huang
- Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - S Li
- Department of Oncology, Zibo Municipal Hospital, Zibo, China
| | - X Meng
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
| |
Collapse
|
15
|
Sun L, Meng X. Enhanced Radiosensitivity of Esophagus Cancer through Loss of ADAR1 and Cell Apoptosis via NF-kB Signaling Pathway. Int J Radiat Oncol Biol Phys 2023; 117:e261. [PMID: 37785001 DOI: 10.1016/j.ijrobp.2023.06.1215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) RNA editing is a common posttranslational mechanism for generating genomic diversity by modifying selected RNA sequences without altering the genome. A new understanding of cancer therapy can be enhanced by the discovery of ADAR1 in the control of signal transduction pathways. However, the study of the biological effects of ADAR1 in radioresistance of esophageal cancer is not very deep. MATERIALS/METHODS The TCGA data sets were used to explore the correlations between ADAR1 and prognosis in esophageal cancer. Two pairs of ADAR1 gene siRNA fragments (siADAR1-1 and siADAR1-2) were designed and transiently transfected into KYSE410 cells and KYSE410-RT cells. The expression of ADAR1 was detected by RT-PCR and WB. Colony formation assay was used to evaluate the radiosensitivity. Apoptosis was measured using a flow cytometric apoptosis assay. Furthermore, transcriptome sequencing was performed to elucidate the pathways regulated by ADAR1. RESULTS In this study, we found that ADAR1 is overexpressed in esophageal tumors and is associated with poor prognosis in bioinformatics analysis. Colony formation experiment showed that siRNA-mediated depletion of ADAR1 in KYSE410 cells could inhibit cell proliferation and reduce radiosensitivity significantly. Consistently results were showed in KYSE410-RT cells. Mechanism studies revealed loss of ADAR1 induced cell apoptosis and radiotherapy could enhance this process. Transcriptomic data indicated that ADAR1 could regulate apoptosis through the NF-kB pathway. CONCLUSION RNA editing was found to be involved in the regulation of radiosensitivity of esophageal cancer and loss of ADAR1 can cause cell apoptosis though NF-kB pathway. A better understanding of A-to-I RNA editing and its oncogenic mechanisms may facilitate the development of radiotherapy in esophageal cancer.
Collapse
Affiliation(s)
- L Sun
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - X Meng
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
16
|
Zhu J, Meng X, Wang B, Tong Q. Experimental Study on Long-Term Mechanical Properties and Durability of Waste Glass Added to OPC Concrete. Materials (Basel) 2023; 16:5921. [PMID: 37687614 PMCID: PMC10488662 DOI: 10.3390/ma16175921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 08/22/2023] [Accepted: 08/25/2023] [Indexed: 09/10/2023]
Abstract
This study aims to achieve the sustainable utilization of waste glass resources through an investigation into the influence of three types of admixtures, namely waste glass powder (WGP) (G), waste glass powder-slag (G-S), and waste glass powder-fly ash (G-F), on the mechanical properties and durability performance of waste glass concrete. The experimental results demonstrate that the exclusive use of WGP as an admixture led to the relatively poor early compressive strength of the concrete, which decreased with an increase in dosage. However, at medium to long curing ages, the strength of the waste glass concrete could equal or even surpass that of ordinary concrete. When dual admixtures were employed, the G-S group exhibited higher compressive strength compared to the G-F group. Specifically, within the G-S group, a glass powder dosage of 15% yielded higher compressive strength, and after 180 days, the dual admixture groups exhibited greater strength than ordinary concrete (G0); the compressive strength of the tG1S1 group was 44.57 MPa, and that of the G0 group was 40.07 MPa. The chloride ion diffusion coefficient showed a varying trend with an increase in WGP dosage, initially decreasing and then increasing. The concrete's resistance to erosion was maximized when the glass powder dosage reached 30%. As the WGP dosage increased, the overall frost resistance decreased. For a total dosage of 30%, the optimal glass powder dosage in both G-S and G-F groups was found to be 15%.
Collapse
Affiliation(s)
- Jichao Zhu
- School of Civil Engineering, Dalian Jiaotong University, Dalian 116028, China; (J.Z.)
- State Key Laboratory of Bridge Engineering Structural Dynamics, China Merchants Chongqing, Communications Technology Research & Design Institute Co., Ltd., Chongqing 400015, China
| | - Xinyu Meng
- School of Civil Engineering, Dalian Jiaotong University, Dalian 116028, China; (J.Z.)
| | - Baoyuan Wang
- School of Civil Engineering, Dalian Jiaotong University, Dalian 116028, China; (J.Z.)
- School of Mechanics & Civil Engineering, China University of Mining and Technology, Xuzhou 221116, China
| | | |
Collapse
|
17
|
Meng H, Zhao Y, Li Y, Fan H, Yi X, Meng X, Wang P, Fu F, Wu S, Wang Y. Evidence for developmental vascular-associated necroptosis and its contribution to venous-lymphatic endothelial differentiation. Front Cell Dev Biol 2023; 11:1229788. [PMID: 37576598 PMCID: PMC10416103 DOI: 10.3389/fcell.2023.1229788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Accepted: 07/17/2023] [Indexed: 08/15/2023] Open
Abstract
During development, apoptosis removes redundant cells and ensures proper organ morphogenesis. Necrosis is long known as an adult-bound inflammatory and pathologic cell death. Whether there exists physiological necrosis during early development has been speculated but yet clearly demonstrated. Here, we report evidence of necroptosis, a type of programmed necrosis, specifically in perivascular cells of cerebral cortex and skin at the early stage of development. Phosphorylated Mixed Lineage Kinase Domain-Like protein (MLKL), a key molecule in executing necroptosis, co-expressed with blood endothelial marker CD31 and venous-lymphatic progenitor marker Sox18. Depletion of Mlkl did not affect the formation of blood vessel network but increased the differentiation of venous-lymphatic lineage cells in postnatal cerebral cortex and skin. Consistently, significant enhancement of cerebrospinal fluid diffusion and lymphatic drainage was found in brain and skin of Mlkl-deficient mice. Under hypobaric hypoxia induced cerebral edema and inflammation induced skin edema, Mlkl mutation significantly attenuated brain-blood-barrier damage and edema formation. Our data, for the first time, demonstrated the presence of physiological vascular-associated necroptosis and its potential involvement in the development of venous-lymphatic vessels.
Collapse
Affiliation(s)
- Han Meng
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Youyi Zhao
- State Key Laboratory of Military Stomatology, National Clinical Research Center for Oral Diseases and Shaanxi Engineering Research, Center for Dental Materials and Advanced Manufacture, Department of Anethesiology, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Yuqian Li
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Hong Fan
- Department of Neurology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China
| | - Xuyang Yi
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Xinyu Meng
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Pengfei Wang
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Fanfan Fu
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Shengxi Wu
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| | - Yazhou Wang
- Department of Neurobiology and Institute of Neurosciences, School of Basic Medicine, Fourth Military Medical University, Xi’an, Shaanxi, China
| |
Collapse
|
18
|
Angelopoulos V, Zhang XJ, Artemyev AV, Mourenas D, Tsai E, Wilkins C, Runov A, Liu J, Turner DL, Li W, Khurana K, Wirz RE, Sergeev VA, Meng X, Wu J, Hartinger MD, Raita T, Shen Y, An X, Shi X, Bashir MF, Shen X, Gan L, Qin M, Capannolo L, Ma Q, Russell CL, Masongsong EV, Caron R, He I, Iglesias L, Jha S, King J, Kumar S, Le K, Mao J, McDermott A, Nguyen K, Norris A, Palla A, Roosnovo A, Tam J, Xie E, Yap RC, Ye S, Young C, Adair LA, Shaffer C, Chung M, Cruce P, Lawson M, Leneman D, Allen M, Anderson M, Arreola-Zamora M, Artinger J, Asher J, Branchevsky D, Cliffe M, Colton K, Costello C, Depe D, Domae BW, Eldin S, Fitzgibbon L, Flemming A, Frederick DM, Gilbert A, Hesford B, Krieger R, Lian K, McKinney E, Miller JP, Pedersen C, Qu Z, Rozario R, Rubly M, Seaton R, Subramanian A, Sundin SR, Tan A, Thomlinson D, Turner W, Wing G, Wong C, Zarifian A. Energetic Electron Precipitation Driven by Electromagnetic Ion Cyclotron Waves from ELFIN's Low Altitude Perspective. Space Sci Rev 2023; 219:37. [PMID: 37448777 PMCID: PMC10335998 DOI: 10.1007/s11214-023-00984-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 06/28/2023] [Indexed: 07/15/2023]
Abstract
We review comprehensive observations of electromagnetic ion cyclotron (EMIC) wave-driven energetic electron precipitation using data collected by the energetic electron detector on the Electron Losses and Fields InvestigatioN (ELFIN) mission, two polar-orbiting low-altitude spinning CubeSats, measuring 50-5000 keV electrons with good pitch-angle and energy resolution. EMIC wave-driven precipitation exhibits a distinct signature in energy-spectrograms of the precipitating-to-trapped flux ratio: peaks at >0.5 MeV which are abrupt (bursty) (lasting ∼17 s, or Δ L ∼ 0.56 ) with significant substructure (occasionally down to sub-second timescale). We attribute the bursty nature of the precipitation to the spatial extent and structuredness of the wave field at the equator. Multiple ELFIN passes over the same MLT sector allow us to study the spatial and temporal evolution of the EMIC wave - electron interaction region. Case studies employing conjugate ground-based or equatorial observations of the EMIC waves reveal that the energy of moderate and strong precipitation at ELFIN approximately agrees with theoretical expectations for cyclotron resonant interactions in a cold plasma. Using multiple years of ELFIN data uniformly distributed in local time, we assemble a statistical database of ∼50 events of strong EMIC wave-driven precipitation. Most reside at L ∼ 5 - 7 at dusk, while a smaller subset exists at L ∼ 8 - 12 at post-midnight. The energies of the peak-precipitation ratio and of the half-peak precipitation ratio (our proxy for the minimum resonance energy) exhibit an L -shell dependence in good agreement with theoretical estimates based on prior statistical observations of EMIC wave power spectra. The precipitation ratio's spectral shape for the most intense events has an exponential falloff away from the peak (i.e., on either side of ∼ 1.45 MeV). It too agrees well with quasi-linear diffusion theory based on prior statistics of wave spectra. It should be noted though that this diffusive treatment likely includes effects from nonlinear resonant interactions (especially at high energies) and nonresonant effects from sharp wave packet edges (at low energies). Sub-MeV electron precipitation observed concurrently with strong EMIC wave-driven >1 MeV precipitation has a spectral shape that is consistent with efficient pitch-angle scattering down to ∼ 200-300 keV by much less intense higher frequency EMIC waves at dusk (where such waves are most frequent). At ∼100 keV, whistler-mode chorus may be implicated in concurrent precipitation. These results confirm the critical role of EMIC waves in driving relativistic electron losses. Nonlinear effects may abound and require further investigation.
Collapse
Affiliation(s)
- V. Angelopoulos
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - X.-J. Zhang
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: University of Texas at Dallas, Richardson, TX 75080 USA
| | - A. V. Artemyev
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | | | - E. Tsai
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - C. Wilkins
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - A. Runov
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - J. Liu
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Atmospheric and Oceanic Sciences Departments, University of California, Los Angeles, CA USA
| | - D. L. Turner
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland USA
| | - W. Li
- Atmospheric and Oceanic Sciences Departments, University of California, Los Angeles, CA USA
| | - K. Khurana
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - R. E. Wirz
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: School of Mechanical, Industrial, and Manufacturing Engineering, Oregon State University, Corvallis, OR 97331 USA
| | - V. A. Sergeev
- University of St. Petersburg, St. Petersburg, Russia
| | - X. Meng
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109 USA
| | - J. Wu
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - M. D. Hartinger
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Space Science Institute, Boulder, CO 80301 USA
| | - T. Raita
- Sodankylä Geophysical Observatory, University of Oulu, Sodankylä, Finland
| | - Y. Shen
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - X. An
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - X. Shi
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - M. F. Bashir
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - X. Shen
- Department of Astronomy and Center for Space Physics, Boston University, Boston, MA USA
| | - L. Gan
- Department of Astronomy and Center for Space Physics, Boston University, Boston, MA USA
| | - M. Qin
- Department of Astronomy and Center for Space Physics, Boston University, Boston, MA USA
| | - L. Capannolo
- Department of Astronomy and Center for Space Physics, Boston University, Boston, MA USA
| | - Q. Ma
- Department of Astronomy and Center for Space Physics, Boston University, Boston, MA USA
| | - C. L. Russell
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - E. V. Masongsong
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - R. Caron
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - I. He
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Materials Science and Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - L. Iglesias
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Deloitte Consulting, New York, NY 10112 USA
| | - S. Jha
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Microsoft, Redmond, WA 98052 USA
| | - J. King
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - S. Kumar
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Department of Astronomy and Astrophysics, The University of Chicago, Chicago, IL 60637 USA
| | - K. Le
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Materials Science and Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - J. Mao
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Raybeam, Inc., Mountain View, CA 94041 USA
| | - A. McDermott
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - K. Nguyen
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: SpaceX, Hawthorne, CA 90250 USA
| | - A. Norris
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - A. Palla
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Reliable Robotics Corporation, Mountain View, CA 94043 USA
| | - A. Roosnovo
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - J. Tam
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - E. Xie
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Deloitte Consulting, New York, NY 10112 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - R. C. Yap
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mathematics Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Planet Labs, PBC, San Francisco, CA 94107 USA
| | - S. Ye
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - C. Young
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Microsoft, Redmond, WA 98052 USA
| | - L. A. Adair
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: KSAT, Inc., Denver, CO 80231 USA
| | - C. Shaffer
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Tyvak Nano-Satellite Systems, Inc., Irvine, CA 92618 USA
| | - M. Chung
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Northrop Grumman Aerospace Systems, Redondo Beach, CA 90278 USA
| | - P. Cruce
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Apple, Cupertino, CA 95014 USA
| | - M. Lawson
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - D. Leneman
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
| | - M. Allen
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Zipline International, South San Francisco, CA 94080 USA
| | - M. Anderson
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mathematics Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Lucid Motors, Newark, CA 94560 USA
| | - M. Arreola-Zamora
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Northrop Grumman Aerospace Systems, Redondo Beach, CA 90278 USA
| | - J. Artinger
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: College of Engineering and Computer Science, California State University, Fullerton, Fullerton, CA 92831 USA
| | - J. Asher
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: The Aerospace Corporation, El Segundo, CA 90245 USA
| | - D. Branchevsky
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: The Aerospace Corporation, El Segundo, CA 90245 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - M. Cliffe
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: SpaceX, Hawthorne, CA 90250 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - K. Colton
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mathematics Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Planet Labs, PBC, San Francisco, CA 94107 USA
| | - C. Costello
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Heliogen, Pasadena, CA 91103 USA
| | - D. Depe
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Argo AI, LLC, Pittsburgh, PA 15222 USA
| | - B. W. Domae
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - S. Eldin
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Microsoft, Redmond, WA 98052 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - L. Fitzgibbon
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Terran Orbital, Irvine, CA 92618 USA
| | - A. Flemming
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Northrop Grumman Aerospace Systems, Redondo Beach, CA 90278 USA
| | - D. M. Frederick
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Millenium Space Systems, El Segundo, CA 90245 USA
| | - A. Gilbert
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Department of Electrical Engineering, Stanford University, Stanford, CA 94305 USA
| | - B. Hesford
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - R. Krieger
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Materials Science and Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Mercedes-Benz Research and Development North America, Long Beach, CA 90810 USA
| | - K. Lian
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: The Aerospace Corporation, El Segundo, CA 90245 USA
| | - E. McKinney
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Geosyntec Consultants, Inc., Costa Mesa, CA 92626 USA
| | - J. P. Miller
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Juniper Networks Sunnyvale, California, 94089 USA
| | - C. Pedersen
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - Z. Qu
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Niantic Inc., San Francisco, CA 94111 USA
| | - R. Rozario
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: SpaceX, Hawthorne, CA 90250 USA
| | - M. Rubly
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Teledyne Scientific and Imaging, Thousand Oaks, CA 91360 USA
| | - R. Seaton
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - A. Subramanian
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Present Address: Northrop Grumman Aerospace Systems, Redondo Beach, CA 90278 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
| | - S. R. Sundin
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Naval Surface Warfare Center Corona Division, Norco, CA 92860 USA
| | - A. Tan
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Electrical and Computer Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Epirus Inc., Torrance, CA 90501 USA
| | - D. Thomlinson
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: The Aerospace Corporation, El Segundo, CA 90245 USA
| | - W. Turner
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Department of Astronomy, Ohio State University, Columbus, OH 43210 USA
| | - G. Wing
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Computer Science Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Present Address: Amazon, Seattle, WA 98109 USA
| | - C. Wong
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Physics and Astronomy Department, University of California, Los Angeles, CA 90095 USA
- Present Address: Department of Radiology, University of California, San Francisco, San Francisco, CA 94143 USA
| | - A. Zarifian
- Earth, Planetary, and Space Sciences Department, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, Los Angeles, CA 90095 USA
- Mechanical and Aerospace Engineering Department, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095 USA
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109 USA
| |
Collapse
|
19
|
Zhou S, Meng X, Fu C, Xu D, Li J, He Q, Lin S, Liang S, Chang Z, Pan A. Aligned Dipoles Induced Electric-Field Promoting Zinc-Ion De-Solvation toward Highly Stable Dendrite-Free Zinc-Metal Batteries. Small 2023:e2303457. [PMID: 37394714 DOI: 10.1002/smll.202303457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/14/2023] [Indexed: 07/04/2023]
Abstract
Water-induced parasitic reactions and uncontrolled dendritic Zn growth are long-lasting tricky problems that severely hinder the development of aqueous zinc-metal batteries. Those notorious issues are closely related to electrolyte configuration and zinc-ion transport behavior. Herein, through constructing aligned dipoles induced electric-field on Zn surface, both the solvation structure and transport behavior of zinc-ions are fundamentally changed. The vertically ordered zinc-ion migration trajectory and gradually concentrated zinc-ion achieved inside the polarized electric-field remarkably eliminate water related side-reactions and Zn dendrites. Zn-metal under the polarized electric-field demonstrated significantly improve reversibility and a dendrite-free surface with strong (002) Zn deposition texturing. Zn||Zn symmetric cell delivers greatly prolonged lifespan up to 1400 h (17 times longer than that of the cell based on bare Zn) while the Zn||Cu half-cell demonstrate ultrahigh 99.9% coulombic efficiency. NH4 V4 O10 ||Zn half-cell delivered exceptional-high 132 mAh g-1 capacity after ultralong 2000 cycles (≈100% capacity retention). In addition, MnO2 ||Zn pouch-cell under aligned dipoles induced electric-field maintains 87.9% capacity retention after 150 cycles under practical condition of high MnO2 mass loading (≈10 mg cm-2 ) and limited N/P ratio. It is considered that this new strategy can also be implemented to other metallic batteries and spur the development of batteries with long-lifespan and high-energy-density.
Collapse
Affiliation(s)
- Shuang Zhou
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Xinyu Meng
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Chunyan Fu
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Dongming Xu
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Jianwen Li
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Qiong He
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Shangyong Lin
- School of Mineral Processing and Bioengineering, Central South University, Changsha, 410083, P. R. China
| | - Shuquan Liang
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Zhi Chang
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| | - Anqiang Pan
- College of Chemistry and Chemical Engineering, School of Materials Science & Engineering, Central South University, Changsha, Hunan, 410083, P. R. China
| |
Collapse
|
20
|
Huang H, Du J, Meng X, Wu D, Yu Y, Wang S, Wang L, Wang W, Tang Y, Li N. Growing research and development of targeted anticancer drugs in China. Journal of the National Cancer Center 2023; 3:129-134. [DOI: 10.1016/j.jncc.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2024] Open
|
21
|
Si Y, Wen J, Hu C, Chen H, Lin L, Xu Y, Ren D, Meng X, Wang Y, Xia E, Bhandari A, Wang O. LINC00891 promotes tumorigenesis and metastasis of thyroid cancer by regulating SMAD2/3 via EZH2. Curr Med Chem 2023:CMC-EPUB-131976. [PMID: 37221682 DOI: 10.2174/0929867330666230522115945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 04/11/2023] [Accepted: 04/14/2023] [Indexed: 05/25/2023]
Abstract
BACKGROUND Thyroid cancer (TC), the most common endocrine malignant tumor, is increasingly causing a huge threat to our health nowadays. METHODS To explore the tumorigenesis mechanism of thyroid cancer, we identified that long intergenic non-coding RNA-00891 (LINC00891) was upregulated in TC using the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and local databases. LINC00891 expression correlated with histological type and lymph node metastasis (LNM). The high expression of LINC00891 could serve as a diagnostic marker for TC and its LNM. In vitro experiments demonstrated that LINC00891 knockdown could inhibit cell proliferation, migration, invasion apoptosis, and of TC cells. We also investigated the related mechanisms of LINC00891 promoting TC progression using RNA sequencing, Gene Set Enrichment Analysis, and Western blotting. RESULTS Our experiments demonstrated that LINC00891 promoted TC progression via the EZH2-SMAD2/3 signaling axis. In addition, overexpression of EZH2 could reverse the suppressive epithelial-to-mesenchymal transition (EMT) caused by LINC00891 knockdown. CONCLUSION In conclusion, the LINC00891/EZH2/SMAD2/3 regulatory axis participated in tumorigenesis and metastasis of thyroid cancer, which may provide a novel target for treatment.
Collapse
Affiliation(s)
- Yuhao Si
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Jialiang Wen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China
| | - Chunlei Hu
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Hao Chen
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Lizhi Lin
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Yiying Xu
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Disuo Ren
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Xinyu Meng
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Yinghao Wang
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Erjie Xia
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| | - Adheesh Bhandari
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
- Department of Surgery, Breast and Thyroid Unit, Primera Hospital, Kathmandu, Nepal
| | - Ouchen Wang
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China
| |
Collapse
|
22
|
Li J, Zhou S, Meng X, Chen Y, Fu C, Azizi A, Zhao X, Xie W, Chang Z, Pan A. Unique ion rectifier intermediate enabled by ultrathin vermiculite sheets for high-performance Zn metal anodes. Sci Bull (Beijing) 2023:S2095-9273(23)00322-5. [PMID: 37258378 DOI: 10.1016/j.scib.2023.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 03/24/2023] [Accepted: 05/02/2023] [Indexed: 06/02/2023]
Abstract
Metallic Zn represents as a primary choice in fabricating various aqueous Zn-ion batteries (ZIBs), while challenging issues include dendrite growth and parasitic reactions at the anode/electrolyte interface, considerably hamper its practical implementation in large-scale energy storage. Herein, we originally develop a low-cost multifunctional ion rectifier (IRT) as an artificial intermediate to reform Zn anode, which can practically eliminate the above issues. The hydrophobic shell (polyvinylidene difluoride) can suppress Zn interfacial corrosion with an inhibition efficiency of 94.8% by repelling water molecules from the bulk electrolyte. Additionally, negatively-charged ion channels inside the zincophilic core (ultrathin vermiculite sheets) induce de-solvating redistribution effect on Zn2+ ions flux, enabling a high ions transference number (0.79) for dendrite-free Zn deposition. This leads to exceptional Zn/Zn2+ reversibility in metallic Zn with IRT stabilization. The remarkable Coulombic efficiency (99.8%, 2000 cycles) for asymmetrical batteries, and a long-lasting lifespan (1600 h) with ultrahigh cumulative capacity of 2400 mAh cm-2 for symmetrical batteries, are successfully achieved. More encouragingly, the Zn//NH4V4O10 pouch cell retains 94.3% of its original capacity after 150 cycles at 1 A g-1. We believe that this low-cost and high-efficiency tactic could pave a promising path for anode surface modification.
Collapse
Affiliation(s)
- Jianwen Li
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China
| | - Shuang Zhou
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China.
| | - Xinyu Meng
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China
| | - Yining Chen
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China
| | - Chunyan Fu
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China
| | - Alireza Azizi
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China
| | - Xiaoguang Zhao
- School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China
| | - Weimin Xie
- School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China
| | - Zhi Chang
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China
| | - Anqiang Pan
- School of Materials Science and Engineering, Key Laboratory of Electronic Packaging and Advanced Functional Materials of Hunan Province, Central South University, Changsha 410083, China.
| |
Collapse
|
23
|
Yang ZM, Huang J, Chen XM, Meng X, Qiu Y, Zeng W, Zhang JQ. [Advances in clinical characteristics of talaromycosis combined with other opportunistic infections]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:503-506. [PMID: 37147814 DOI: 10.3760/cma.j.cn112147-20220807-00659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Talaromycosis (TSM) is an opportunistic deep mycosis prevalent in southeast Asia and southern China, affecting HIV-positive, anti-interferon-gamma autoantibody-positive and other immunodeficiency hosts. These hosts are often co-infected with mycobacterium tuberculosis, non-tuberculosis mycobacteria, bacteria, fungi, viruses and other opportunistic infections. The clinical characteristics and the pathogenic spectrum of TSM with opportunistic infections vary with different immune states. The rates of misdiagnosis, missed diagnosis and mortality are high. This review summarized the clinical characteristics of TSM with opportunistic infections in order to improve the level of clinical diagnosis and treatment.
Collapse
Affiliation(s)
- Z M Yang
- Department of Respiratory and Critical Medicine, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| | - J Huang
- Department of Respiratory and Critical Care Medicine, the Fourth People's Hospital of Nanning, Nanning 530002, China
| | - X M Chen
- Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
| | - X Meng
- Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
| | - Y Qiu
- Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - W Zeng
- Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
| | - J Q Zhang
- Department of Respiratory and Critical Medicine, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| |
Collapse
|
24
|
Fan C, Li J, Li Y, Jin Y, Feng J, Guo R, Meng X, Gong D, Chen Q, Du F, Zhang C, Lu L, Deng J, Chen X. Hypoxia-inducible factor-1α regulates the interleukin-6 production by B cells in rheumatoid arthritis. Clin Transl Immunology 2023; 12:e1447. [PMID: 37179532 PMCID: PMC10167477 DOI: 10.1002/cti2.1447] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 03/27/2023] [Accepted: 04/04/2023] [Indexed: 05/15/2023] Open
Abstract
Objectives Rheumatoid arthritis (RA) is a disease characterised by bone destruction and systemic inflammation, and interleukin-6 (IL-6) is a therapeutic target for treating it. The study aimed at investigating the sources of IL-6 and the influence of hypoxia-inducible factor-1α (HIF-1α) on IL-6 production by B cells in RA patients. Methods The phenotype of IL-6-producing cells in the peripheral blood of RA patients was analysed using flow cytometry. Bioinformatics, real-time polymerase chain reaction, Western blot and immunofluorescence staining were used to determine the IL-6 production and HIF-1α levels in B cells. A dual-luciferase reporter assay and chromatin immunoprecipitation were used to investigate the regulatory role of HIF-1α on IL-6 production in human and mouse B cells. Results Our findings revealed that B cells are major sources of IL-6 in the peripheral blood of RA patients, with the proportion of IL-6-producing B cells significantly correlated with RA disease activity. The CD27-IgD+ naïve B cell subset was identified as the typical IL-6-producing subset in RA patients. Both HIF-1α and IL-6 were co-expressed by B cells in the peripheral blood and synovium of RA patients, and HIF-1α was found to directly bind to the IL6 promoter and enhance its transcription. Conclusion This study highlights the role of B cells in producing IL-6 and the regulation of this production by HIF-1α in patients with RA. Targeting HIF-1α might provide a new therapeutic strategy for treating RA.
Collapse
Affiliation(s)
- Chaofan Fan
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Jia Li
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yixuan Li
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yuyang Jin
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Jiaqi Feng
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Ruru Guo
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Xinyu Meng
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Dongcheng Gong
- China‐Australia Centre for Personalised Immunology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Qian Chen
- Department of Ophthalmology, Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
- Shanghai Key Laboratory of Fundus DiseaseShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Fang Du
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Chunyan Zhang
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Liangjing Lu
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Jun Deng
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji HospitalShanghai Jiao Tong University School of Medicine (SJTUSM)ShanghaiChina
| | - Xiao‐Xiang Chen
- Department of Rheumatology, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
| |
Collapse
|
25
|
Lyu JJ, Yan BY, Feng Y, Meng X, Zhao X, Dou X, Liang XF, Wang FZ, Xu AQ, Zhang L. [Persistence follow-up of immune memory to hepatitis B vaccine among infants with non- and low-response to primary vaccination after revaccination with three doses]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:732-735. [PMID: 37165820 DOI: 10.3760/cma.j.cn112150-20220511-00468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
This study followed up the immune memory after 3-dose revaccination among infants with non-and low-response following primary hepatitis B (HepB) vaccination. About 120 children without self-booster doses were finally included who had anti-HBs<10 mIU/ml (anti-HBs negative) at the time of follow-up, of whom 86 children completed blood sampling and anti-HBs testing. Before the challenge dose, all 86 children were negative for anti-HBs, and the GMC of anti-HBs was<10 mIU/ml. The seropositive conversion rate of anti-HBs was 100% and the GMC of anti-HBs was 886.11 (95%CI: 678.15-1 157.84) mIU/ml after the challenge dose. Compared with those with GMC<7 mIU/ml before the challenge dose, infants with GMC>7 mIU/ml had a higher anti-HBs level after the challenge dose. The β value (95%CI) was 0.82 (0.18-1.46) (P=0.012). Compared with those with GMC<1 000 mIU/ml at primary vaccination, infants with GMC≥1 000 mIU/ml had a higher anti-HBs level after the challenge dose. The β value (95%CI) was 0.78 (0.18-1.38)(P=0.012). The results showed a stronger immune memory was found at 9 years after revaccination among infants with non-and low-response to HepB.
Collapse
Affiliation(s)
- J J Lyu
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - B Y Yan
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China
| | - Y Feng
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China
| | - X Meng
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China
| | - X Zhao
- School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - X Dou
- School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - X F Liang
- School of Medicine, Jinan University, Guangzhou 510632, China
| | - F Z Wang
- Center for National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - A Q Xu
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - L Zhang
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| |
Collapse
|
26
|
Zhou S, Meng X, Fu C, Chen J, Chen Y, Xu D, Lin S, Han C, Chang Z, Pan A. Lithiophilic Magnetic Host Facilitates Target-Deposited Lithium for Practical Lithium-Metal Batteries. Small 2023; 19:e2207764. [PMID: 36869407 DOI: 10.1002/smll.202207764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 01/31/2023] [Indexed: 05/25/2023]
Abstract
Lithium-metal shows promising prospects in constructing various high-energy-density lithium-metal batteries (LMBs) while long-lasting tricky issues including the uncontrolled dendritic lithium growth and infinite lithium volume expansion seriously impede the application of LMBs. In this work, it is originally found that a unique lithiophilic magnetic host matrix (Co3 O4 -CCNFs) can simultaneously eliminate the uncontrolled dendritic lithium growth and huge lithium volume expansion that commonly occur in typical LMBs. The magnetic Co3 O4 nanocrystals which inherently embed on the host matrix act as nucleation sites and can also induce micromagnetic field and facilitate a targeted and ordered lithium deposition behavior thus, eliminating the formation of dendritic Li. Meanwhile, the conductive host can effectively homogenize the current distribution and Li-ion flux, thus, further relieving the volume expansion during cycling. Benefiting from this, the featured electrodes demonstrate ultra-high coulombic efficiency of 99.1% under 1 mA cm-2 and 1 mAh cm-2 . Symmetric cell under limited Li (10 mAh cm-2 ) inspiringly delivers ultralong cycle life of 1600 h (under 2 mA cm-2 , 1 mAh cm-2 ). Moreover, LiFePO4 ||Co3 O4 -CCNFs@Li full-cell under practical condition of limited negative/positive capacity ratio (2.3:1) can deliver remarkably improved cycling stability (with 86.6% capacity retention over 440 cycles).
Collapse
Affiliation(s)
- Shuang Zhou
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Xinyu Meng
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Chunyan Fu
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Jing Chen
- School of Physics and Materials, Nanchang University, Nanchang, 330031, P.R. China
| | - Yining Chen
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Dongming Xu
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Shangyong Lin
- School of Mineral Processing and Bioengineering, Central South University, Changsha, 410083, P.R. China
| | - Chao Han
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Zhi Chang
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| | - Anqiang Pan
- State Key Laboratory of Powder Metallurgy, School of Materials Science & Engineering, Central South University, Changsha, 410083, P.R. China
| |
Collapse
|
27
|
Zhang R, Han W, Zhang L, Wang L, Meng X. Provably Secure Receiver-Unrestricted Group Key Management Scheme for Mobile Ad Hoc Networks. Sensors (Basel) 2023; 23:s23094198. [PMID: 37177401 PMCID: PMC10181436 DOI: 10.3390/s23094198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 03/29/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023]
Abstract
Mobile ad hoc networks (MANETs) are self-configuring networks of wireless nodes, i.e., mobile devices. Since communications in MANETs occur via wireless channels, it is of significance to secure communications among wireless and mobile nodes. Group key management, as a widely used method for securing group communications, has potentially been used in MANETs for years. Most recently, a secure receiver-unrestricted group key management scheme for MANETs has been proposed, which is used to establish a secure channel among a group of wireless nodes without a trusted dealer, which has some advantages such as eliminating the certificate management problem and receiver restriction. However, a formal security analysis of this scheme is still lacking. Therefore, in this paper, we propose the complete security proof to demonstrate that the scheme satisfies the essential security properties including authentication, message confidentiality, known-key security and dynamic secrecy. We also give a brief discussion about the efficiency of the scheme.
Collapse
Affiliation(s)
- Rui Zhang
- Shanghai Key Laboratory of Trustworthy Computing, Software Engineering Institute, East China Normal University, Shanghai 200062, China
- Guangxi Key Laboratory of Cryptography and Information Security, Guilin 541004, China
- Science and Technology on Communication Security Laboratory, Chengdu 610041, China
- Engineering Research Center of Software/Hardware Co-Design Technology and Application, Ministry of Education, East China Normal University, Shanghai 200062, China
| | - Wendie Han
- Shanghai Key Laboratory of Trustworthy Computing, Software Engineering Institute, East China Normal University, Shanghai 200062, China
- Guangxi Key Laboratory of Cryptography and Information Security, Guilin 541004, China
- Science and Technology on Communication Security Laboratory, Chengdu 610041, China
- Engineering Research Center of Software/Hardware Co-Design Technology and Application, Ministry of Education, East China Normal University, Shanghai 200062, China
| | - Lei Zhang
- Shanghai Key Laboratory of Trustworthy Computing, Software Engineering Institute, East China Normal University, Shanghai 200062, China
- Guangxi Key Laboratory of Cryptography and Information Security, Guilin 541004, China
- Science and Technology on Communication Security Laboratory, Chengdu 610041, China
- Engineering Research Center of Software/Hardware Co-Design Technology and Application, Ministry of Education, East China Normal University, Shanghai 200062, China
| | - Lulu Wang
- Shanghai Key Laboratory of Trustworthy Computing, Software Engineering Institute, East China Normal University, Shanghai 200062, China
- Guangxi Key Laboratory of Cryptography and Information Security, Guilin 541004, China
- Science and Technology on Communication Security Laboratory, Chengdu 610041, China
- Engineering Research Center of Software/Hardware Co-Design Technology and Application, Ministry of Education, East China Normal University, Shanghai 200062, China
| | - Xinyu Meng
- College of Information Engineering, Shanghai Maritime University, Shanghai 201306, China
| |
Collapse
|
28
|
Peng J, Meng R, Liu X, Zhang L, Wang L, Feng R, Feng H, Huang Z, Yao D, Li X, Liu N, Tan B, Li S, Yu J, Meng X. 172P A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00426-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
29
|
Li W, Yang N, Li K, Fan H, Yu Q, Wu H, Wang Y, Meng X, Wu J, Wang Z, Liu Y, Wang X, Qin X, Lu K, Zhuang W, He S, Janne P, Seto T, Ou SH, Zhou C. 14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC). J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00268-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
30
|
Huang H, Tang Y, Wu D, Meng X, Wang S, Wang J, Yu Y, Fang Y, Fang H, Zhu Q, Li N, Xu B, Sun Y, He J. Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution. BMC Geriatr 2023; 23:199. [PMID: 36997858 PMCID: PMC10064764 DOI: 10.1186/s12877-023-03886-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 03/13/2023] [Indexed: 04/01/2023] Open
Abstract
BACKGROUND Older adults are a growing segment of oncology population in China and beyong. However, older cancer patients were vastly underrepresented in clinical trial. To facilitate that all patients with cancer have equal access to the cutting edging treatment and receive evidence-based medication in mainland China, it's of particular importance to fully grasp the proportion of upper age restriction in cancer clinical trials, as well as associated factors. METHODS Based on clinical trials registered on the China Food and Drug Administration Registration and Information Disclosure Platform, we sought to characterize the overall proportion and trajectory of upper age-restriction among registered cancer drug trials in mainland China from 2009 to 2021, and potential influencing factors were determined by multivariate logistic regression. RESULTS According to the 3485 trials, upper age restriction proportion of cancer drug trials for patients over 65 years and 75 years was 18.8% (95% CI = 17.5%-20.1%) and 56.5% (95% CI = 51.3%-54.6%), respectively. Phase IV trials, international multicenter trials, or trials initiated by global companies seldom excluded patients over 65 years compared with phase I trials, domestic trials and trials initiated by Chinese enterprise, similar for 75 years and above. Both of 65 and 75 years old age limit sponsored by domestic enterprises showed slowly downward trend, while no such trend was observed for that of foreign companies. Solution to upper age eligibility of cancer drug trials was also provided. CONCLUSIONS Although there is a certain downward trend, use of eligibility criteria that explicitly exclude older cancer patients in mainland China was remarkably high, especially for trials initiated by domestic enterprise, domestic trials and early-phase trials. Action is urgently needed to promote treatment equity in the older patients while obtaining adequate evidence in clinical trials.
Collapse
Affiliation(s)
- Huiyao Huang
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Yu Tang
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Dawei Wu
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Xinyu Meng
- School of Population and Global Health, the University of Melbourne, Victoria, 3010, Australia
| | - Shuhang Wang
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Jun Wang
- Center for Drug Evaluation, National Medical Products Administration, Beijing, 100022, China
| | - Yue Yu
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Yuan Fang
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Hong Fang
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Qi Zhu
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China
| | - Ning Li
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China.
| | - Binghe Xu
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Yan Sun
- Clinical Trial Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, People's Republic of China
| | - Jie He
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| |
Collapse
|
31
|
Shen Z, Gao E, Meng X, Xu J, Sun Y, Zhu J, Li J, Wu Z, Wang W, Yao S, Dai Q. Mechanistic Insight into Catalytic Combustion of Ethyl Acetate on Modified CeO 2 Nanobelts: Hydrolysis-Oxidation Process and Shielding Effect of Acetates/Alcoholates. Environ Sci Technol 2023; 57:3864-3874. [PMID: 36812295 DOI: 10.1021/acs.est.2c07991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
In this study, based on the comparison of two counterparts [Mn- and Cr-modified CeO2 nanobelts (NBs)] with the opposite effects, some novel mechanistic insights into the ethyl acetate (EA) catalytic combustion over CeO2-based catalysts were proposed. The results demonstrated that EA catalytic combustion consisted of three primary processes: EA hydrolysis (C-O bond breakage), the oxidation of intermediate products, and the removal of surface acetates/alcoholates. Rapid EA hydrolysis typically occurs on surface acid/base sites or hydroxyl groups, and the removal of surface acetates/alcoholates resulting from EA hydrolysis is considered the rate-determining step. The deposited acetates/alcoholates like a shield covered the active sites (such as surface oxygen vacancies), and the enhanced mobility of the surface lattice oxygen as an oxidizing agent played a vital role in breaking through the shield and promoting the further hydrolysis-oxidation process. The Cr modification impeded the release of surface-activated lattice oxygen from the CeO2 NBs and induced the accumulation of acetates/alcoholates at a higher temperature due to the increased surface acidity/basicity. Conversely, the Mn-substituted CeO2 NBs with the higher lattice oxygen mobility effectively accelerated the in situ decomposition of acetates/alcoholates and facilitated the re-exposure of surface active sites. This study may contribute to a further mechanistic understanding into the catalytic oxidation of esters or other oxygenated volatile organic compounds over CeO2-based catalysts.
Collapse
Affiliation(s)
- Zude Shen
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Erhao Gao
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Xinyu Meng
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Jiacheng Xu
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Yan Sun
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Jiali Zhu
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Jing Li
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Zuliang Wu
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Wei Wang
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Shuiliang Yao
- School of Environmental Science and Engineering, Changzhou University, Changzhou 213164, Jiangsu, P. R. China
| | - Qiguang Dai
- Key Laboratory for Advanced Materials, Research Institute of Industrial Catalysis, School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai 200237, P. R. China
| |
Collapse
|
32
|
Fan Y, Xu Y, Huang Z, Hong W, Gong L, Chen K, Qin J, Xie F, Wang F, Tian X, Meng X, Feng W, Li L, Zhang B, Kang X. 29P A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
33
|
Liu H, Meng X, Li L, Xia Y, Hu X, Fang Y. The incorporated hydrogel of chitosan-oligoconjugated linoleic acid vesicles and the protective sustained release for curcumin in the gel. Int J Biol Macromol 2023; 227:17-26. [PMID: 36502952 DOI: 10.1016/j.ijbiomac.2022.12.049] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 12/05/2022] [Accepted: 12/06/2022] [Indexed: 12/13/2022]
Abstract
Assemblies of as called "chitosan hydrogel-liposome" are expected for overcoming the burst effect in drug release from chitosan (CS) hydrogels. Herein, a hydrogel delivery system made of chitosan incorporated fatty acid vesicles was constructed for protective sustained release of curcumin (Cur). The curcumin was encapsulated in the prepared oligo-conjugated linoleic acid vesicles (OCLAVs), and then the drug-embedded vesicles were constructed to Cur-OCLAVs-CS hydrogels with CS solution. The fabricated Cur-OCLAVs-CS hydrogel was fluidic at room temperature and could be rapidly gelled at 37 °C. Morphology study proves that the OCLAVs stayed as nano-vesicles in the gel. The Cur-OCLAVs-CS hydrogels effectively declined the burst effect with enhanced antioxidant activity. The Cur (400 μM)-OCLAVs-CS gel presented a cumulative release rate of 51.23 % of curcumin in 96 h, comparing to 93.37 % of that from the Cur-CS gel. Moreover, the corporation of OCLAVs and CS made the gel exhibited strong synergistic effect on the antioxidant activity, with an enhancement of up to 148.1 % on the ferric reducing power. Therefore, the hydrogel carrier made of incorporated fatty acid vesicles-chitosan can be served as an injectable or 3D printable drug delivery system, which may provide a hint to overcome the burst effect that existed in chitosan and other polysaccharide-based gels.
Collapse
Affiliation(s)
- Huan Liu
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China; School of Chemical and Material Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Xinyu Meng
- School of Chemical and Material Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Lei Li
- School of Chemical and Material Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Yongmei Xia
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China; School of Chemical and Material Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China.
| | - Xueyi Hu
- School of Chemical and Material Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Yun Fang
- School of Chemical and Material Engineering, Jiangnan University, Wuxi, Jiangsu 214122, China
| |
Collapse
|
34
|
Jin P, Gao Y, Fu Z, Yang W, Meng X. 105P Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
35
|
Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, Meng X, Wang S, Zhu Q, Wang X, Du J, Yang Z, Li N, Xu B, He J. Accelerating the integration of China into the global development of innovative anticancer drugs. Lancet Oncol 2022; 23:e515-e520. [PMID: 36328025 DOI: 10.1016/s1470-2045(22)00483-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 07/11/2022] [Accepted: 07/15/2022] [Indexed: 11/06/2022]
|
36
|
Zhai L, Meng X, Meng Z, Wang W, Jin N. Quasi-3D visualization and local parameter measurement of horizontal and nearly horizontal liquid–liquid two-phase flows by using PLIF method. Chem Eng Sci 2022. [DOI: 10.1016/j.ces.2022.118063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Chen Y, Wang Y, Ren F, Huang Z, Tan B, Zhao Z, Yu X, Dong P, Yu J, Meng X. Prophylactic Cranial Irradiation (PCI) vs. Active Surveillance in Patients with Limited-Stage Small Cell Lung Cancer: A Retrospective, Multicenter study. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Su YY, Li M, D'Arcy C, Caron J, O'Donnell K, Meng X. To what extent do social support and mastery mediate the association between childhood maltreatment and depression? A sequential causal mediation analysis. Epidemiol Psychiatr Sci 2022; 31:e77. [PMID: 36263598 PMCID: PMC9677445 DOI: 10.1017/s2045796022000609] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
AIMS This study aimed to examine the independent roles of various childhood maltreatment (CM) subtypes in the development of depression; quantify the joint mediation effect of social support and mastery in the association between subtypes of CM and depression and examine the additional contribution of mastery beyond the effect that is operating through social support to this relationship. METHODS Data analysed were from the Zone d'Épidémiologie Psychiatrique du Sud-Ouest de Montréal, an ongoing longitudinal population-based study. In total, 1351 participants with complete information on the studied variables were included. The propensity score matching and inverse-probability weighted regression adjustment estimation methods were used to minimise the potential confounding in the relationship between CM and major depression. We then used inverse odds ratio-weighted estimation to estimate the direct effects of maltreatment and indirect effects of social support and mastery. RESULTS We found that exposures to all maltreatment subtypes increased the risk of subsequent depression. The joint mediating effect of social support and mastery explained 37.63-46.97% of the association between different maltreatment subtypes and depression. The contribution of these two mediators differed by maltreatment subtypes, with social support being the major contributor to the mediating effect. CONCLUSIONS The findings of the study not only provide scientific evidence on the importance of psychosocial attributes in the development of major depression but also suggest that prevention and invention strategies should focus on these psychosocial attributes to effectively break the vicious cycle of CM on major depression.
Collapse
Affiliation(s)
- Y. Y. Su
- Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
- Douglas Research Centre, Montreal, QC, Canada
| | - M. Li
- Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
- Douglas Research Centre, Montreal, QC, Canada
| | - C. D'Arcy
- School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada
- Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
| | - J. Caron
- Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
- Douglas Research Centre, Montreal, QC, Canada
| | - K. O'Donnell
- Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
- Douglas Research Centre, Montreal, QC, Canada
- Yale Child Study Center & Department of Obstetrics Gynecology & Reproductive Sciences, Yale School of Medicine, Yale University, New Haven, CT, USA
- Child & Brain Development Program, CIFAR, Toronto, ON, Canada
| | - X. Meng
- Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
- Douglas Research Centre, Montreal, QC, Canada
- Author for correspondence: X. Meng, E-mail:
| |
Collapse
|
39
|
Wood J, Meng X, Meyers L, Blekeny C, Sztajnkrycer M. 281 Out-of-Hospital TXA Administration Opportunities in Trauma Patients Transported by ALS Ground EMS - A Descriptive Study. Ann Emerg Med 2022. [DOI: 10.1016/j.annemergmed.2022.08.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
40
|
Tang Y, Meng X, Yu X, Shang H, Chen S, Liao L, Dong J. Retraction Note to: Inhibition of microRNA‑875‑5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium-iodide symporter. J Endocrinol Invest 2022; 45:2025. [PMID: 35836040 DOI: 10.1007/s40618-022-01852-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Y Tang
- Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, No. 16766, Jingshi Road, Jinan, 250014, Shandong Province, People's Republic of China
- Department of Endocrinology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China
| | - X Meng
- Department of Endocrinology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China
| | - X Yu
- Department of Endocrinology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China
| | - H Shang
- Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, No. 16766, Jingshi Road, Jinan, 250014, Shandong Province, People's Republic of China
| | - S Chen
- Department of Endocrinology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China
| | - L Liao
- Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, No. 16766, Jingshi Road, Jinan, 250014, Shandong Province, People's Republic of China.
| | - J Dong
- Department of Endocrinology, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Jinan, 250012, Shandong Province, People's Republic of China.
| |
Collapse
|
41
|
Guo R, Liu X, Li Y, Meng X, Li R, Chen X, Lu L. AOSD Endotypes based on immune cell profiles: patient stratification with hierarchical clustering analysis. Rheumatology (Oxford) 2022; 62:1636-1644. [PMID: 35972374 DOI: 10.1093/rheumatology/keac439] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 07/22/2022] [Accepted: 07/22/2022] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES This study aimed to analyse the immune cell profiles of adult-onset Still's disease (AOSD) and to stratify disease-associated endotypes. METHODS We included 95 cases of treatment-naïve patients with AOSD and 66 cases of healthy controls (HCs). Patients with AOSD were classified via an unbiased hierarchical cluster analysis based on circulating immune cells. Their clinical and laboratory characteristics, treatment management, systemic scores, and outcomes were then analysed. RESULTS The proportions of neutrophils and CD8+ T cells were significantly higher while monocytes and natural killer and CD4+ T cells were decreased in patients with AOSD (all p < 0.005). Unbiased hierarchical cluster analysis classified 95 AOSD into three endotype-based groups: group 1 had the highest percentage of neutrophils (Neu-dominant group), group 2 had the highest percentage of monocytes (Mono-dominant group), and group 3 had the highest percentage of CD8+ T cells (CD8-dominant group). Patients in group 3 had the highest systemic score at diagnosis and were more likely to have pulmonary infiltrates, pericarditis, splenomegaly, and poorer treatment responses. A correlation study revealed that the CD4 to CD8 ratio was negatively correlated with the systemic score and positively correlated with treatment response in patients with AOSD (p = 0.001 and p = 0.0091). During the 24.6 ± 15.2 months of follow-up, the highest total number of disease flares occurred in group 3 (p < 0.0001). CONCLUSION Hierarchical cluster analysis of peripheral immune cells classified AOSD into three disease-related endotypes. Group 3 showed higher systemic score and poorer treatment responses.
Collapse
Affiliation(s)
- Ruru Guo
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China
| | - Xuesong Liu
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China.,Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Rd, Shanghai, 200127, P. R. China
| | - Yixuan Li
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China
| | - Xinyu Meng
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China
| | - Rui Li
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China
| | - Xiaoxiang Chen
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China
| | - Liangjing Lu
- Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 145 Middle Shandong Rd, 200001, P. R. China
| |
Collapse
|
42
|
Liu H, Hu X, Li L, Meng X, Fang Y, Xia Y. Micron and nano hybrid ufasomes from conjugated linoleic acid, their vesiculation and encapsulation of ginsenoside Rg3. J Sci Food Agric 2022; 102:4140-4150. [PMID: 34997612 DOI: 10.1002/jsfa.11763] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 12/25/2021] [Accepted: 01/08/2022] [Indexed: 06/14/2023]
Abstract
BACKGROUND Unsaturated fatty acids used to form unstable micro-vesicles, while conjugate linoleic acid (CLA)-sodium dodecyl sulfate (SDS) can self-assembly to stable nano-conjugate linoleic acid vesicles (nano-CLAVs). Generally, micro-capsule could geometrically provide higher loading capacity but also generate concerns in construction convenience, sustained release, bioaccessibility and stability. Hence there is a contradiction between loading capacity and encapsulation efficiency. Therefore, the study of the factors that decide the capsule size falling in nano or micron size with same capsule material would be a benefit to food or drug delivery science. RESULTS The micron- and nano-CLAVs were constructed for encapsulation and sustained release of ginsenoside Rg3. The formation mechanism of nano or micron capsule,s the effect of vesicle sizes on encapsulation efficiency, drug loading efficiency and stability of the encapsulated Rg3 were investigated. It was found that with the addition of salt (PBS), the size of CLAVs jumped from nano to micron. Furthermore, the salt concentration is the key factor that decides the vesicle size of nano or micron. The pH at fabrication triggers the vesiculation and dramatically affects the vesicle size over the nano and micron scales. CONCLUSION Compared to the nano-CLAVs, micron vesicles enhanced the loading capacity to 137.6% and the encapsulation efficiency to 138.4%, respectively. Meanwhile, the micron-CLAVs performed similar sustained release of Rg3 as the nano-CLAVs did, and was stable for 120 days at room temperature or sustained 98.9% of capsules after centrifuge at 6090 × g for 20 min. © 2022 Society of Chemical Industry.
Collapse
Affiliation(s)
- Huan Liu
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China
- School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China
| | - Xueyi Hu
- School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China
| | - Lei Li
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China
- School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China
| | - Xinyu Meng
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China
- School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China
| | - Yun Fang
- School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China
| | - Yongmei Xia
- State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China
- School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China
| |
Collapse
|
43
|
Huang H, Zhu Q, Ga M, Wu D, Meng X, Wang S, Fang H, Tang Y, Li N. Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States. Front Oncol 2022; 12:930846. [PMID: 35936746 PMCID: PMC9355250 DOI: 10.3389/fonc.2022.930846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 06/20/2022] [Indexed: 12/04/2022] Open
Abstract
Objective To systematically summarize the landscape and characteristics of all approved new anticancer drugs for the last 10 years in China and the United States (US) to further inform the trend, current state, and existing gap in the availability and affordability of cancer medicine between the two countries. Methods Mainly based on the Pharmcube database, a list and detailed information of anticancer drugs approved in China and the United States were acquired. The annual number, time lag, and basic characteristics, including drug type, mechanism, enterprise type, indication population, drug target, and cancer type of approved drugs were compared. Results Eighty-seven and 118 new anticancer drugs were approved in China and the US, respectively, showing a stable trend in the US, while a significant increase was observed after 2016 in China. Of the 42 cancer medicines launched in both countries, the US took precedence, and the median time lag markedly decreased, from 6.53 years in 2012 to 0.88 years in 2020. A total of 14.4% of drugs were applicable to children in the US, while only 2.3% were applicable in China, and there was no difference in drug type and enterprise. Thirty-one and 43 targets were explored, with respect to 27 and 36 cancer types in China and the US, respectively, during the period. In addition, the expenditure of drugs on PD-1 and PD-L1 in China was generally lower than that in America. Conclusion The availability of new anticancer drugs has increased dramatically in the past decade, particularly in China. Compared with the US, the launch of new anticancer drugs in China lags behind, but the time lag has been shortened significantly, and better affordability is observed in immune drugs. More attention should be given to differentiated innovation, and unmet medical needs in special populations like childhood tumors, which are important directions of new drug R&D in China.
Collapse
Affiliation(s)
- Huiyao Huang
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qi Zhu
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
| | - Man Ga
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Dawei Wu
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xinyu Meng
- Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia
| | - Shuhang Wang
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Hong Fang
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yu Tang
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ning Li
- Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- *Correspondence: Ning Li,
| |
Collapse
|
44
|
Meng X, Lyu JJ, Feng Y, Dou X, Zhao X, Liang XF, Wang FZ, Xu AQ, Yan BY, Zhang L. [Anti-HBs persistence after primary vaccination with three doses of 5 μg recombinant hepatitis B vaccine among normal and high-responder infants: 10-year of follow-up]. Zhonghua Yu Fang Yi Xue Za Zhi 2022; 56:794-799. [PMID: 35785861 DOI: 10.3760/cma.j.cn112150-20210630-00620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: Assess the 10-year Immune persistence and the predictors after primary vaccination hepatitis B vaccine (HepB) among normal and high-responder infants. Methods: A total of 1 838 Infants of 7-12 months old located in Jinan, Weifang, Yantai and Weihai of Shandong Province who were induced normal or high antibody response (anti-HBs titer ≥ 100 mIU/ml) after primary vaccination (three dose with 0-1-6 procedure) with 5 μg recombinant HepB among newborns were included in the study, in 2009. 3 ml of venous blood samples were collected at baseline survey (T0) and antibodies against hepatitis B surface antigen (anti-HBs), antibody against hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were detected using chemiluminescence microparticle immunoassay (CMIA) method. A self-designed questionnaire was used to collect information including the infant's age, sex, birth weight, premature birth, birth number, delivery location and mother's HBV infection status. In 2014 (followed up for 5 years) and in 2019 (followed up for 10 years) (T1), 2 ml of venous blood samples were collected. Anti HBS and anti HBC were detected by CMIA method. Those with anti HBS<10 mIU/ml were detected by CMIA method. Multivariate unconditional logistic and linear regression models were used to analyze the influencing factors of anti-HBs positive rate and geometric mean concentration (GMC) at T1. Results: After 10 years follow-up, 73.94% of the subjects (1 359/1 835) finished the follow-up. 51.15% of the subjects, a total of 625 were boys. The positive rate of anti-HBs was 100% at T0 and decreased to 53.44% (95%CI: 50.59%-56.26%) at T1. The average annual decline rate of anti-HBs positive rate from T0 to T1 was 6.07%. The GMC of anti-HBs decreased from 607.89 (95%CI: 579.01-642.62) mIU/ml to 16.44 (95%CI: 15.06-18.00) mIU/ml. The average annual decline rate of anti-HBs GMC in 10-year follow-up was 30.30%. Multivariate logistic analysis showed that the positive rate of anti-HBs at T1 was lower in those who did not vaccinate the first dose in time (OR=0.25, 95%CI:0.07-0.71). Compared with those with GMC<1 000 mIU/ml at T0, those with GMC ≥ 1 000 mIU/ml had a higher positive rate of anti-HBs at T1 (OR=2.29, 95%CI:1.76-2.97). Multivariate regression analysis showed that the GMC of anti-HBs at T1 was lower in those who did not vaccinate the first dose in time (β=-0.50, 95%CI:-1.24-0.24). Compared with those with GMC<1 000 mIU/ml at T0, those with GMC ≥ 1 000 mIU/ml had a higher GMC of anti-HBs at T1 (β=0.81, 95%CI: 0.62-1.05). Conclusion: Anti-HBs GMC decreased in 10 years after primary vaccination of 5 μg recombinant hepatitis B vaccine among normal and high-responders. The anti-HBs persistence was mainly associated with whether the first dose was vaccinated in time and the level of anti-HBs at the end of primary vaccination.
Collapse
Affiliation(s)
- X Meng
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Institute for Preventive Medicine of Shandong University, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China
| | - J J Lyu
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Institute for Preventive Medicine of Shandong University, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China
| | - Y Feng
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Institute for Preventive Medicine of Shandong University, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China
| | - X Dou
- School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - X Zhao
- School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - X F Liang
- Chinese Preventive Medicine Association, Beijing 100021, China
| | - F Z Wang
- Center for National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - A Q Xu
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Institute for Preventive Medicine of Shandong University, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - B Y Yan
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Institute for Preventive Medicine of Shandong University, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China
| | - Li Zhang
- Expanded Program Immunizatin Division, Shandong Provincial Center for Disease Control and Prevention, Institute for Preventive Medicine of Shandong University, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China School of Pubic Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| |
Collapse
|
45
|
Jin C, Zhang C, Ni X, Zhao Z, Xu L, Wu B, Chi Y, Jiajue R, Jiang Y, Wang O, Li M, Xing X, Meng X, Xia W. The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study. Osteoporos Int 2022; 33:1385-1395. [PMID: 35088103 PMCID: PMC9106624 DOI: 10.1007/s00198-021-06221-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 10/19/2021] [Indexed: 11/03/2022]
Abstract
UNLABELLED The present study was the first prospective cohort evaluated the efficacy and safety of different doses of calcitriol in XLH children. The results suggested that a dose of 40 ng/kg/day calcitriol, compared with 20 ng/kg/day, was more effective in relieving the rickets, with similar safety outcomes. Further investigations were expected to set more dose groups. INTRODUCTION Dose recommended for calcitriol in X-linked hypophosphatemia (XLH) varies in different studies. Therefore, we aimed to compare the efficacy as well as the safety of 20 ng/kg/d and 40 ng/kg/d calcitriol in Chinese XLH pediatrics population. METHODS A 2-year, randomized, open-label, prospective study recruited 68 XLH children, which were randomized to receive either 40 ng/kg/day or 20 ng/kg/day calcitriol. Efficacy endpoints were the total Thacher ricket severity score (RSS) change from baseline to month 12 and 24, the difference in serum TALP level, fasting serum phosphate level, body height Z-score, and frequency of dental abscess. Safety assessments were done using renal ultrasound nephrocalcinosis grades (0-4), fasting serum and 24 h urine calcium level, and the occurrence of hyperparathyroidism. RESULTS The decrease in the total RSS from baseline was more significant in the high-dose group at 12 (difference 0.87, p = 0.049) and 24 month (difference 1.23, p = 0.011). The serum TALP level was significantly lower in the high-dose group at 6 months. Pi level, height Z-score change, frequency of dental abscess and ratio of de novo nephrocalcinosis were comparable. A lower incidence of secondary hyperparathyroidism was seen in the high-dose group (p < 0.0001). CONCLUSION For the first time in this prospective cohort, 40 ng/kg/d calcitriol was shown to be the more effective therapy in XLH children than the 20 ng/kg/d. Moreover, 40 ng/kg/d calcitriol was not associated with increasing adverse events. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT 03,820,518.
Collapse
Affiliation(s)
- C Jin
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - C Zhang
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - X Ni
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - Z Zhao
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - L Xu
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - B Wu
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - Y Chi
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - R Jiajue
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - Y Jiang
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - O Wang
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - Mei Li
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - X Xing
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - X Meng
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China
| | - W Xia
- Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730, China.
| |
Collapse
|
46
|
Ritchlin CT, Orbai AM, Parikh B, Gaillez C, Meng X, Mease PJ. POS1016 RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundFor patients with psoriatic arthritis (PsA), delays in diagnosis and treatment can lead to permanent radiographic damage, even early in the course of disease.1 In the phase 3 FUTURE 5 study (NCT02404350), treatment with secukinumab (SEC) was shown to inhibit progression of structural damage through Week 104 in patients with PsA.2 However, the effect of disease duration on inhibition of radiographic progression by SEC has not been characterized.ObjectivesThis post hoc analysis explored relationships between time since diagnosis (TSD) of ≤1 year vs >1 year and radiographic progression among patients with PsA receiving SEC over 2 years in FUTURE 5.MethodsPatient data from FUTURE 5 were stratified by TSD ≤1 year vs >1 year and analyzed by treatment arm. Through Week 24, patients received SEC 300 or 150 mg with subcutaneous loading dose (LD), SEC 150 mg without LD, or placebo (PBO) (period 1). After Week 24, patients receiving PBO were switched to SEC 300 or 150 mg (period 2), and a protocol amendment allowed those with suboptimal clinical response to SEC 150 mg to escalate to SEC 300 mg after Week 52 per investigator judgment.2 The proportion of patients with no radiographic progression, defined as change from baseline in van der Heijde total modified Sharp score ≤0.0, was analyzed at Weeks 24, 52, and 104. Mean total Sharp score was evaluated at baseline, and mean change from baseline was determined at Weeks 24, 52, and 104.ResultsOf 996 patients with PsA included here, 217 (21.8%) had a TSD ≤1 year and 779 (78.2%) had a TSD >1 year. At baseline, patients with TSD >1 year had greater radiographic damage than patients with TSD ≤1 year as determined by mean total Sharp score (Table 1). As early as Week 24, patients receiving SEC had less radiographic progression than those receiving PBO, regardless of TSD. From Week 24 to Week 104, radiographic progression remained low among all patients receiving SEC, with a trend of least progression among patients randomized to SEC 300 mg at baseline. Regardless of treatment, patients with TSD >1 year had numerically greater radiographic progression than those patients with TSD ≤1 year. Overall, the proportion of patients receiving SEC who did not have any radiographic progression was higher than that of placebo at Week 24 irrespective of TSD, with a trend towards a higher number of non-progressors among those treated with SEC 300 mg (Figure). Patients randomized to SEC 300 mg were the least likely to experience radiographic progression through 52 weeks.Table 1.Baseline Total Sharp Score and Change From Baseline at Weeks 24, 52, and 104 by TSDTotal Sharp scoreTSD ≤1 yearTSD >1 yearPeriod 1SEC 300 mg n = 54SEC 150 mg n = 46SEC 150 mg NL n = 43PBO n = 74SEC 300 mg n = 168SEC 150 mg n = 174SEC 150 mg NL n = 179PBO n = 258Baseline, mean (SD)8.02 (20.77)8.82 (12.06)12.74 (33.67)8.84 (20.42)14.37 (24.17)14.67 (28.01)15.56 (37.52)17.34 (41.21)Week 24 change from baseline, mean (SD)0.05 (0.72)−0.08 (1.40)−0.61 (5.25)0.76 (2.05)0.09 (1.37)0.23 (1.24)0.03 (2.05)0.42 (1.56)Period 2SEC 300 mg* n = 54SEC 150 mg†n = 46SEC 150 mg NL†n = 43PBO ‒ 300 mg n = 40PBO ‒ 150 mg†n = 30SEC 300 mg* n = 168SEC 150 mg†n = 174SEC 150 mg NL†n = 179PBO ‒ 300 mg n = 113PBO ‒ 150 mg†n = 123Week 52 change from baseline, mean (SD)0.05 (0.48)−0.03 (1.22)0.35 (2.25)0.22 (0.70)0.18 (0.75)−0.07 (1.16)0.26 (1.96)0.26 (1.05)0.16 (0.94)0.40 (2.00)Week 104 change from baseline, mean (SD)0.06 (0.63)0.11 (0.99)0.20 (2.71)0.11 (0.68)−0.07 (0.50)0.11 (2.00)0.62 (2.94)0.46 (2.08)0.12 (0.90)0.81 (2.66)NL, no loading dose; PBO, placebo; SEC, secukinumab; TSD, time since diagnosis.* One outlier in the 300-mg dose group was excluded.† Includes patients who received dose escalation to SEC 300 mg after Week 52.ConclusionSEC resulted in low rates of radiographic progression through 2 years of treatment among patients in FUTURE 5, regardless of time since PsA diagnosis.References[1]Haroon M, et al. Ann Rheum Dis. 2015;74:1045-50.[2]Mease P, et al. RMD Open. 2021;7:e001600.AcknowledgementsThis study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Richard Karpowicz, PhD, CMPP, of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.Disclosure of InterestsChristopher T. Ritchlin Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, Novartis, Gilead, and UCB, Ana-Maria Orbai Consultant of: Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis, Bhumik Parikh Employee of: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Corine Gaillez Employee of: Novartis Pharma AG, Basel, Switzerland, Xiangyi Meng Employee of: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB
Collapse
|
47
|
Cao S, Song R, Meng X, Kachler K, Fuchs M, Meng X, Li Y, Taudte V, Kunz M, Schloetzer-Schrehardt U, Schleicher U, Chen X, Schett G, Bozec A. OP0076 L-ARGININE REPROGRAMS OSTEOCLAST PURINE METABOLISM AMELIORATING BONE LOSS IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundBone erosion is a clinical feature of rheumatoid arthritis related to disease severity and poor functional prognosis. Excessive osteoclast differentiation and insufficient osteoblast function are the main reasons for the erosive process in RA. Our previous investigation indicated that L-arginine supplementation not only diminished arthritic inflammation in the serum-induced arthritis (K/BxN) model but also decreased inflammatory joints osteoclast numbers (1).ObjectivesIn the present study, we aim to investigate the metabolic action of L-arginine supplementation in RA, especially on periarticular bone erosion and systemic bone loss. We plan to depict the metabolic features of TNFα induced inflammatory osteoclasts after in vitro L-arginine supplementation.MethodsThree murine arthritis models (serum-induced arthritis (K/BxN) model, collagen-induced arthritis model, and hTNFtg mice model) were analysed in this study. L-arginine was supplemented within the drinking water after the onset of arthritis. Bone parameters for axial skeleton (spine) and peripheral skeleton (tibia) from the respective group were quantified by μCT. HE and TRAP staining were performed to address further the erosion area and osteoclast numbers in periarticular sites. In vitro osteoclast differentiation was conducted with or without L-arginine treatment, in the presence or not of TNFα activation. Seahorse and SCENITH analyses were adopted to delineate the metabolic features. JC-1 staining and transmission electron microscopy (TEM) were used to depict the mitochondria metabolism. RNA-seq and mass spectrometry (MS) were performed to investigate the underlying molecular mechanism.ResultsInflammation was diminished in all three arthritis models after L-arginine supplementation with a significant reduction in arthritic score. Moreover, an amelioration of periarticular bone erosion, systemic bone loss, and decreased osteoclast numbers in periarticular sites were observed in arthritic mice after L-arginine treatment. L-arginine also inhibited osteoclastogenesis in vitro, particularly under TNFα activation. Seahorse and SCENITH analyses indicated TNFα promoted glycolysis while blocking mitochondria-driven oxidative phosphorylations (OXPHOS) in pre-osteoclasts. Meanwhile, JC-1 staining and TEM images also showed that TNFα decreased mitochondria membrane potential and prompted damage of mitochondria. Surprisingly, L-arginine rescued the TNFα inhibition of OXPHOS while promoting ATP production.RNA-seq and MS data confirmed the boost of OXPHOS after L-arginine treatment under TNFα activation. To interfere with OXPHOS, L-arginine inhibited cJun thus altered arginase-1 and arginase-2 expression. Moreover, the increased ATP in L-arginine treated cells facilitated purine metabolism, especially the production of inosine and hypoxanthine, contributing to the inhibition of osteoclastogenesis. Increasing Adenosine deaminase (ADA) is essential for the production of inosine and hypoxanthine due to the decreased inhibitory regulation of the transcription factor c-Jun.ConclusionThese data strongly demonstrated that L-arginine ameliorates bone erosion in RA through metabolic reprogramming and perturbation of purine metabolism in osteoclasts. L-arginine might therefore benefit RA therapy by reducing joint inflammation and also ameliorating bone destruction.References[1]Hannemann, Nicole, et al. “Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis.” The Journal of clinical investigation 129.7 (2019): 2669-2684.Disclosure of InterestsShan Cao: None declared, Rui Song: None declared, Xianyi Meng: None declared, Katerina Kachler: None declared, Maximilian Fuchs: None declared, Xinyu Meng: None declared, Yixuan Li: None declared, Verena Taudte: None declared, Meik Kunz: None declared, Ursula Schloetzer-Schrehardt: None declared, Ulrike Schleicher: None declared, Xiaoxiang Chen Speakers bureau: AbbVie, Roche and Novartis, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Aline Bozec: None declared.
Collapse
|
48
|
Lyu P, Wen J, Stolzer I, Giessl A, Song R, Meng X, Cao S, Günther C, Schett G, Bozec A. POS0409 INTESTINAL HIF1α EXPRESSION PROTECTS AGAINST EPITHELIAL CELL DEATH IN ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundWhile a so-called gut-joint axis is supported by many clinical observations, the current knowledge on such axis is mostly confined to descriptive and correlative data, e.g. showing the microbiota changes are associated with arthritis. In contrast, mechanistic data on how molecular changes in the intestinal epithelium influence the development of arthritis are scarce.ObjectivesTo investigate, whether the mucosal barrier in the intestine dependent of the epithelial cell survival maintenance, influences the development of arthritis.MethodsIntestinal hypoxia inducible factor (HIF)-1α expression was assessed before, at onset and during experimental arthritis and human rheumatoid arthritis (RA). Intestinal epithelial cell-specific HIF1α conditional knock-out mice were generated (HIF1αΔIEC) and subjected to collagen-induced arthritis (CIA). Clinical and histological courses of arthritis were recorded, and T and B cell subsets were analyzed in the gut and secondary lymphatic organs, and intestinal epithelial cells were subjected to molecular mRNA sequencing in HIF1αΔIEC and littermate control mice. Furthermore, pharmacologic HIF1α stabilization by PHD inhibitor was used for the treatment of arthritis.ResultsIntestinal HIF1α expression peaked at onset and remained high in experimental arthritis and RA. Conditionally deletion of HIF1α in gut epithelial cells strongly exacerbate arthritis and was associated with increased gut epithelial cell death, intestinal and lymphatic Th1 and Th17 activation. Mechanistically, HIF1α inhibits the transcription of necroptotic and apoptotic markers, which leads to a defect in the intestinal barrier integrity. Furthermore, treatment with HIF1α stabilization reinforced the gut epithelial cell survival and inhibited arthritis.ConclusionThese findings show that the HIF1α regulating epithelial cells survival is critical for the breakdown of the intestinal barrier function in arthritis highlighting the functional link between intestinal homeostasis and arthritis.Disclosure of InterestsNone declared.
Collapse
|
49
|
Mease PJ, Orbai AM, Parikh B, Gaillez C, Meng X, Ritchlin CT. POS1022 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5 DURING THE FIRST 24 WEEKS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients with active psoriatic arthritis (PsA) experience inflammation that may result in structural damage and disability. In the phase 3 FUTURE 5 study, treatment with secukinumab (SEC) inhibited radiographic progression and led to sustained remission and low disease activity (LDA) through Week 104.1,2ObjectivesThis post hoc analysis of FUTURE 5 explored relationships between radiographic progression status and achievement of LDA or remission in patients treated with SEC.MethodsPatients were randomized 2:2:2:3 to receive SEC 300 mg with loading dose (LD), 150 mg LD, SEC 150 mg without LD, or placebo (PBO) at Baseline, Weeks 1, 2, 3, 4, and every 4 weeks thereafter until Week 24. In this post hoc analysis, patients were grouped by radiographic progression status at Week 24 (non-radiographic progressors: change from baseline in modified total Sharp score [mTSS] ≤0.0; radiographic progressors: change from baseline in mTSS >0.0). Efficacy (achievement of Minimal Disease Activity [MDA] or Very Low Disease Activity [VLDA] and their individual components, and Disease Activity Index for Psoriatic Arthritis [DAPSA] LDA or remission) was assessed at Week 24.ResultsOf 933 patients with available data, 675 (72.3%) were classified as non-radiographic progressors and 258 (27.7%) were radiographic progressors at Week 24. Non-progressors at Week 24 were more likely than progressors to achieve DAPSA LDA and remission at Week 24 across all treatment arms (Figure 1A). In addition, non-progressors were more likely to achieve MDA and VLDA at Week 24 than progressors across all treatment arms (Figure 1B). Similar trends were observed for all of the individual MDA/VLDA criteria at Week 24 among patients treated with SEC 300 mg or SEC 150 mg LD (Table 1). Notably, non-progressors were more likely to achieve improvements in physical function, pain, and patient global assessment of disease activity than progressors across all treatment arms.Table 1.Proportion of Patients Achieving MDA/VLDA Components at Week 24 Grouped by Radiographic Progression Status at Week 24Week 24 non-progressorsWeek 24 progressorsOutcome, n/N (%)SEC 300 mg n = 166SEC 150 mg n = 150SEC 150 mg NL n = 159PBO n = 200SEC 300 mg n = 51SEC 150 mg n = 63SEC 150 mg NL n = 51PBO n = 93TJC78 ≤152/161 (32.3)46/146 (31.5)37/150 (24.7)38/196 (19.4)15/50 (30.0)13/62 (21.0)13/49 (26.5)11/90 (12.2)SJC76 ≤1105/160 (65.6)85/146 (58.2)83/150 (55.3)88/196 (44.9)32/50 (64.0)28/62 (45.2)20/49 (40.8)30/90 (33.3)PASI ≤1 or BSA ≤3%99/128 (77.3)90/128 (70.3)69/109 (63.3)64/153 (41.8)29/38 (76.3)27/47 (57.4)28/40 (70.0)26/70 (37.1)Patient pain VAS ≤1557/144 (39.6)50/133 (37.6)50/141 (35.5)33/179 (18.4)14/42 (33.3)15/60 (25.0)13/43 (30.2)7/82 (8.5)PtGA VAS ≤2063/145 (43.4)47/125 (37.6)50/135 (37.0)39/173 (22.5)13/41 (31.7)14/61 (23.0)13/41 (31.7)7/81 (8.6)HAQ-DI ≤0.572/135 (53.3)55/118 (46.6)54/122 (44.3)47/158 (29.7)13/39 (33.3)18/58 (31.0)17/39 (43.6)19/77 (24.7)Tender entheseal points ≤170/87 (80.5)44/63 (69.8)42/76 (55.3)45/88 (51.1)13/18 (72.2)17/31 (54.8)11/19 (57.9)23/38 (60.5)BSA, body surface area; HAQ-DI, Health Assessment Questionnaire Disability Index; MDA, Minimal Disease Activity; NL, no loading dose; PASI, Psoriasis Area and Severity Index; PBO, placebo; PtGA, patient global assessment of disease activity; SEC, secukinumab; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale; VLDA, Very Low Disease Activity.ConclusionPatients who did not have radiographic progression over 6 months of SEC treatment were more likely to achieve LDA or remission and improvement in physical function at Week 24. Additional analyses will explore relationships between radiographic progression and additional clinical and patient-reported outcomes over longer time periods.References[1]Mease P, et al. RMD Open. 2021;7:e001600.[2]Coates LC, et al. Ann Rheum Dis. 2021;80:803-4.AcknowledgementsThis study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.Disclosure of InterestsPhilip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Ana-Maria Orbai Consultant of: Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: To Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis, Bhumik Parikh Employee of: Novartis Pharmaceuticals Corporation, Corine Gaillez Employee of: Novartis Pharma AG, Xiangyi Meng Employee of: Novartis Pharmaceuticals Corporation, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, Novartis, Gilead, and UCB
Collapse
|
50
|
Fan M, Xia J, Meng X, Zhang K. Single-Phase Grounding Fault Types Identification Based on Multi-Feature Transformation and Fusion. Sensors (Basel) 2022; 22:s22093521. [PMID: 35591212 PMCID: PMC9100241 DOI: 10.3390/s22093521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 04/27/2022] [Accepted: 04/28/2022] [Indexed: 12/10/2022]
Abstract
The frequent occurrence of single-phase grounding faults affects the reliable operation of power systems. When a single-phase grounding fault occurs, it is difficult to accurately identify the fault type because of the weak characterization and subtle distinction between different fault types. Therefore, this paper proposes a single-phase grounding fault type identification method based on the multi-feature transformation and fusion. Firstly, the Hilbert–Huang transform (HHT) was used to preprocess the fault recorded wave data to highlight the characteristics between different fault types. Secondly, the deep learning model ResNet18 and the long short-term memory (LSTM) are designed to extract the complex abstract features and time-series correlation features from the preprocessed data set separately. Finally, it designs a fusion model to combine the advantages of heterogeneous models to identify the type of single-phase grounding fault. Experiments validate that the method is good at fully mining the characteristics of the fault types contained in the fault recorded wave data, so it can identify multiple types of faults with strong robustness and provide a reliable basis for the subsequent formulation of targeted fault-handling measures.
Collapse
Affiliation(s)
- Min Fan
- Correspondence: ; Tel.: +86-023-6510-2490
| | | | | | | |
Collapse
|